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Short summary 
In this thesis finite dose skin absorption experiments were evaluated with respect to 
experimental setup and mathematical modelling. To increase the comparability between 
experiment and modelling, the experiments need to be carefully assessed. Thus, the use of 
infrared densitometry was judged suitable to quantify SC on tape-strips in vitro to increase 
the accuracy of the obtained concentration depth profiles in the SC.  
In vivo, usually a small dose of the formulation is applied to the skin, a so-called finite dose. 
Finite dose skin absorption experiments were performed, which are closer to the in vivo 
reality. The influence of non-homogeneous donor surface distribution was investigated with 
respect to the permeated drug amount as this had not been done before. A dependence on 
the physicochemical parameters of the drug was found.  
With the knowledge obtained before, finite dose skin penetration experiments were 
performed. The experimental data was analyzed with different mathematical models. A 
pharmacokinetic model developed for this study could describe the mass profiles in all 
compartments well, even in the lateral skin part. A 2D diffusion model previously developed 
for infinite dose and adapted to finite dose could predict the mass profiles and 
concentration depth profiles of finite dose experiments for the model drugs caffeine and 
flufenamic acid reasonably.  
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Kurzzusammenfassung 
In dieser Arbeit wurden finite dose Hautabsorptionsversuche evaluiert im Hinblick auf 
experimentellen Aufbau und mathematische Modellierung. Um die Vergleichbarkeit 
zwischen Experiment und Mathematik zu verbessern, müssen die Versuche sorgfältig 
überprüft werden. Deshalb wurde Infrarot Densitometrie untersucht und als geeignet 
befunden, SC auf Tape-strips in vitro zu quantifizieren, um die Präzision von 
Konzentrationsschichttiefenprofilen im SC zu erhöhen. 
In vivo wird üblicherweise eine kleine Donormenge auf die Haut aufgetragen, eine 
sogenannte finite dose. Finite dose Hautabsorptionsversuche wurden durchgeführt, ähnlich 
der in vivo Situation. Der Einfluss von inhomogener Donorverteilung auf der Hautoberfläche 
wurde in Abhängigkeit der permeierten Arzneistoffmenge analysiert, was bisher noch nicht 
getan wurde. Es wurde eine Abhängigkeit von den physikochemischen Eigenschaften des 
Arzneistoffes gefunden. 
Mit dem zuvor erhaltenen Wissen wurden Hautpenetrationsversuche mit finiter Dosierung 
durchgeführt. Die experimentellen Daten wurden mit verschiedenen mathematischen 
Modellen analysiert. Ein für diese Studie entwickeltes pharmakokinetisches Modell konnte 
die Massenprofile in allen Kompartimenten gut beschreiben, sogar im lateralen Hautteil. Ein 
zuvor für infinite dose entwickeltes und nun für finite dose adaptiertes 2D Diffusionsmodell 
konnte die Massenprofile und Konzentrationsschichttiefenprofile für die Modellarzneistoffe 
Coffein und Flufenaminsäure plausibel vorhersagen. 
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1.1 Absorption pathways of the skin  
Even though the skin is a strong barrier for exogenous substances into the body, it has 
become an interesting target for drug absorption. Mainly, this is due to the large surface 
area of the skin, and of the possibility of easy and pain free application of the drug.  
1.1.1 Structure of the skin 
The skin is the biggest organ of the human body with a surface area of 1.7 to 2 m² and a 
weight of more than 10% of the body mass. It is the outer barrier between the body and the 
environment and protects the body from external influences.  
The skin is made up of three cellular layers, of which each has its own structure and function. 
The outermost cellular layer of the skin is the epidermis, which itself can be divided into the 
viable epidermis consisting of living cells, and the non-viable stratum corneum (SC). The 
latter is the strongest barrier of the skin. The dermis lies directly underneath the epidermis 
and consists of compact connective tissue nerved with blood and lymph vessels. These 
supply the epidermis with nutrients and remove absorbed exogenous substances, acting as 
sink. The subcutaneous fatty tissue consists of loose connective tissue, and its dimensions 
vary greatly on different regions and individuals.  
For further information about the anatomical structure of the skin, the reader is referred to 
[1-3].  
 
Stratum corneum (SC) 
The SC as the outermost layer of the epidermis is normally between 10 and 25 µm thick and 
consists of 15 to 25 layers of corneocytes [4,5]. These are completely cornified squamous 
epithelial cells, which are around 1 µm thick. They consist mainly of keratin, a structure 
protein with high mechanical and chemical stability. Each corneocyte is surrounded by a 
cornified envelope, which allows for covalent linkage with the intercellular lipids. The 
corneocytes are embedded in a lipid matrix, which is arranged in lipid bilayers and consists 
of ceramides, free fatty acids, and cholesterol.  
This characteristic structure of the SC is represented in the so called brick-and-mortar model 
[6] (fig. 1-1). In this model, the bricks represent the corneocytes embedded in the mortar as 
the lipid phase.  
  1 Introduction 
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Figure 1-1 Brick and mortar model of the SC and possible penetration pathways through the SC. 
Modified from [2] and [7].   
 
1.1.2 Application to the skin 
When describing the application of a formulation to the skin, different cases can be 
distinguished: formulation remaining on the skin, or absorption to the skin, which can be 
further divided into penetration and permeation (fig. 1-2).  
The formulation remaining on the skin surface is the part of the formulation that does not 
enter the skin and is not absorbed into the skin. For certain formulations, this is the target 
site and the whole formulation should remain on the surface to protect the skin, e.g. 
sunscreens.  
Penetration refers to the absorption of a substance into the different skin layers, which is 
important e.g. for locally acting drugs and most cosmetic products. Therefore, penetration 
experiments are mostly performed on full-thickness skin to account for the different skin 
layers available for the drug, e.g. the SC and the deeper skin layers. To determine the 
penetrated amount in the different layers, skin segmentation is required (for details see 
chapter 10 Appendix).  
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When a substance during incubation penetrates only into the upper SC layers, it is not 
completely lost for further absorption. Instead, it was shown that the SC may act as a 
reservoir for certain substances [8,9]. For glucocorticoids, a skin blanching effect after re-
occlusion of pre-incubated skin could be shown [10]. In another study, the antifungal drug 
miconazole remained in the SC for 24 h after removal of the drug formulation [11].  
Permeation on the other hand is defined as the transport of a substance across a membrane 
into an acceptor. In the case of skin, the permeated drug amount becomes systemically 
bioavailable after reaching the blood vessels. This aspect is most relevant in the context of 
transdermal therapeutic systems, but also to assess systemic toxicity of compounds applied 
to the skin. Permeation experiments are often carried out with thinner skin layers, e.g. heat-
separated epidermis. As blood vessels can be found below the viable epidermis, the 
permeation through heat-separated epidermis represents the absorption of a substance into 
the systemic circulation.  
 
 
Figure 1-2 Absorption to the skin: Penetration vs. permeation illustrated on histological cross-sections of 
full-thickness skin stained with haematoxylin at 200 x magnification.   
 
1.1.3 Pathways across the SC 
Based on its anatomical structure the skin acts as a strong barrier both for exogenous 
substances into the body and for endogenous substances out of the body, e.g. water 
evaporation from the skin. The SC with its unique brick and mortar structure is the most 
important layer for the barrier function of the skin. When a substance is applied to intact 
skin different absorption pathways across the SC are possible (fig. 1-1).  
  1 Introduction 
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• Along the skin appendages (macroscopic ways) 
The appendages route is composed of both glandular and follicular pathways, of which the 
latter one seems to be predominant. Recent studies report that the follicular route may be 
of particular relevance to liposomes and nanoparticles [12,13], even though they only 
contribute to around 0.1% to 1% of the skin surface area [4,14,15].  
A pump effect is discussed, which could transport the particles deep into the hair follicle by 
movement of the hair [13].  
 
• Across the intact stratum corneum (microscopic ways) 
In general, the transport through the SC is regarded as a passive diffusion process. Two 
pathways are possible: 
 
Intercellular route 
The intercellular route is considered as the predominant one for most compounds. In this 
case, substance transport occurs within the continuous, bilayer-structured intercellular lipid 
domain of the SC. Although this pathway is very tortuous due to corneocyte overlapping 
[16,17] and, hence much longer than the total thickness of the SC, it is considered to result in 
much faster absorption due to a higher diffusion coefficient of most substances within the 
lipid phase compared to the corneocytes [18,19]. As in the intercellular route diffusion 
occurs in the identical medium, partition effects are not relevant.  
 
Transcellular route 
Normally, the transcellular route is considered as of minor importance for dermal absorption 
due to low permeability of most substances in the corneocytes. In this transport route, 
substances have to partition from the hydrophilic corneocytes to the intercellular lipid layers 
of the SC and vice versa several times. However, the transcellular pathway may become 
more important after application of a penetration enhancer, e.g. urea. Thus, the 
permeability of the corneocytes increases due to alteration of the keratin structure.   
Recently, the transcellular pathway has been investigated and may be more relevant than 
expected before [18-20].  
The barrier function of the skin can easily be determined by measuring the TEWL 
(transepidermal water loss) in vivo. In this method, the amount of water evaporating 
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through the skin per time and area is measured. As this method is non-invasive, it is often 
used for cosmetic studies, e.g. to show that the barrier function of the skin is restored after 
application of a certain formulation.  
In normal skin, there is always a certain amount of water leaving the skin to the 
environment. On most anatomical sites values of less than 10 g/m²*h can be found [21,22]. 
If the barrier function of the skin is disturbed, e.g. by tape-stripping or contact with 
detergents, the TEWL might reach values of 40 g/m²*h or higher [23,24]. Similar values are 
obtained on intact skin on certain anatomical sites, e.g. the palms of the hands [22].  
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1.2 In vitro skin absorption experiments  
Quantitative data on the bioavailability of compounds applied to the skin are of increasing 
interest, not only for the pharmaceutical, but also for the cosmetic industry. Apart from 
studying the efficacy of a substance, information on the rate and extent of dermal and 
transdermal absorption is most relevant also for the safety assessment for all kinds of 
xenobiotics, such as e.g. sun blockers or pesticides. In fact, such information is explicitly 
requested by the EU initiative REACH - Registration, Evaluation, Authorisation and 
Restriction of Chemicals [25].  
Clinical studies, i.e. in vivo experiments on humans, will always remain the gold standard to 
proof the safety and efficacy of drugs in dermal therapy. However, considering ethic aspects 
as well as high costs of clinical studies, pre-clinical in vitro skin absorption models are still 
very valuable as development tools and frequently used for such purposes. Also, detailed 
knowledge of the skin absorption process, such as e.g. drug distribution into the deeper skin 
layers or accumulation in a distinct skin layer is not readily available from in vivo 
experiments. 
Besides, since 2009 in vivo animal testing of cosmetic products is banned by EU regulation 
76/768/EEC throughout the European Union [26]. Therefore, other techniques must be used 
to obtain the desired information. One possibility is the use of in vitro penetration and 
permeation models. General instructions concerning skin absorption studies are provided by 
the OECD Guideline 428 [27] in combination with Guidance document 28 [28], Scientific 
Committee on Consumer Products [29], by the European Commission [4], and the Food and 
Drug Administration (FDA) of the United States [30]. However, all of these documents lack 
detailed information on practically suitable methods.  
Experiments have shown that in vitro experiments are predictive for in vivo skin absorption 
[31-36]. In vitro permeation and penetration experiments with excised human skin are 
therefore useful tools to obtain knowledge of drug transport across or into the skin, 
respectively. 
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1.2.1 Tissues used for in vitro skin absorption experiments 
Due to its good accessibility, the volar forearm is commonly used for human in vivo studies, 
whereas for in vitro studies, mostly abdominal or breast skin is used. Dependent on the 
anatomical region, the absorption rate through the skin might be up to 40 fold different [37]. 
Human skin is usually obtained from cadavers, plastic surgery or amputations. The skin can 
be used either directly after excision or after proper storage in a freezer. Storage for several 
months without impairment of the barrier function is possible, provided that repeated 
thawing and freezing of the skin is avoided [38-41]. The advantage of fresh skin is that a 
certain metabolic activity may be maintained during the experiments, which is essential 
when skin absorption is influenced by active metabolic processes. However, it is generally 
assumed for most substances that the skin absorption is a passive diffusion process and that 
the main absorption barrier is the SC. Furthermore, the absence of dermal blood flow in vitro 
may build up a significant hindrance to diffusion [42]. Moreover, reducing the membrane 
thickness will generally reduce the run time of an experiment and thus minimize the risk of 
microbial contamination. 
Full-thickness skin is often used for penetration experiments since information about all skin 
layers can be gained. For permeation experiments full-thickness skin is often not 
appropriate, because the permeated amount is quite low and the diffusion resistance of the 
dermis is over predicted [43].  
In that case, full-thickness skin can be treated with a dermatome, which cuts a surface-
parallel skin layer with a defined thickness. Dermatomed skin or split skin comprises 
epidermis including SC and parts of the dermis. Dermatomed skin is often used in a thickness 
between 200 to 400 µm for human skin [28,44].  
Heat-separated epidermis can be prepared by complete removal of the dermis by 
mechanical, thermal or chemical techniques. Usually, the epidermis is split from the dermis 
by placing the skin in water of 60°C for 30-120 seconds [45]. It has been shown that the 
barrier function was not impaired by this treatment [43,46].  
Finally, the stratum corneum may be isolated by enzymatic digestion of the connective 
epidermal tissue. This may be achieved by complete immersion of full-thickness skin in a 
trypsin solution buffered at pH 7.4 or by placing heat-separated epidermis on a filter paper 
soaked with the enzyme preparation for 24 h at 37°C [32,45]. 
  1 Introduction 
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Human skin is preferred for all in vitro skin experiments, as animal skin often leads to 
different absorption behaviour [47,48]. However, sources of human skin are limited and 
therefore alternatives may be required. Due to its high similarity to human skin, both in 
morphology and permeability, pig skin is a convenient alternative [49]. Skin of other animal 
species should only be used, if the method is fully validated. For comparison of relative 
permeability of different formulations only, animal skin, preferably from hairless strains, 
might be useful. Nonetheless, the results need to be confirmed by relevant additional 
experiments.  
Due to the limited availability of human skin, there has been an increasing demand for 
bioengineered human skin equivalents, of which several have become commercially 
available and been evaluated for their use as in vitro dermal absorption models. However, a 
first validation study has revealed that bioengineered human skin equivalents have a 
significantly lower barrier function than natural human skin and thus a much higher 
permeability for the tested compounds [50]. Nevertheless, bioengineered skin epidermis 
equivalents have been shown to be suitable for corrosivity and phototoxicity testing [51]. 
Recently, reconstructed skin equivalents have been validated for corrosion testing and 
approved by the OECD [26,52].  
Even when using human skin, care has to be taken to choose the appropriate set-up and 
preparation of the tissue, depending on the objectives of the study. However, if these critical 
points are correctly addressed, skin absorption studies in vitro may provide valuable 
information. 
1.2.2 In vitro skin permeation models 
Over the last decades, many methods have been designed to study drug transport through 
the skin (permeation) and drug distribution within the different skin layers (penetration). 
This information is essential for pharmaceutical and medical applications with respect to 
drug invasion, drug bioavailability and safety aspects as well as for risk assessment of 
chemicals [25]. 
For years, researchers have used variations of two-compartment in vitro test systems to 
measure the diffusion of a compound from one side of a membrane to the other. Different 
setups have been compared previously [53]. Both static and dynamic diffusion cells are 
available and approved by the authorities [28,44].  
  1 Introduction 
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In general, a donor compartment is separated from an acceptor compartment by a 
membrane of native skin, specific skin layers, or some artificial skin equivalents. Samples 
from the acceptor compartment, usually a physiological buffer solution of pH 7.4, can either 
be taken continuously or at pre-determined time points.  
Experiments should be carried out in a way that surface temperature is 32°C mimicking the 
in vivo situation. The temperature may be controlled by a water bath, a water jacket around 
each cell, or by placing the diffusion cell in a drying oven.  
To simplify data analysis, experiments are generally run under sink conditions. These are 
generally maintained as long as no more than 10% of the compound has been transported 
out of the donor compartment [44]. Moreover, to maintain sink conditions, no more than 
10% of the saturation concentration of the drug in the acceptor should be reached [28]. If 
not, the absorption might be reduced by low solubility of the drug in the acceptor fluid.  
 
Franz Diffusion Cell 
The most commonly used permeation test system is the static Franz diffusion cell [31]. The 
Franz diffusion cell consists of a donor compartment and an acceptor compartment (fig. 1-3) 
with the appropriate membrane sandwiched between these two compartments. The donor 
compartment contains the drug preparation, which might be an ointment, a solution or even 
a patch. The chamber beneath the membrane holds an acceptor fluid, which is continuously 
mixed with a magnetic stir bar.  
The Franz diffusion cell combines many advantages: It is an inert, robust instrument, which is 
easy to handle. It is maintainable at a constant temperature and has precisely calibrated 
volumes and diffusion areas, and it facilitates easy sampling and replenishment of the 
acceptor medium.  
The permeation behaviour of a substance through the membrane can be determined by 
sampling at predefined time points. Aliquots of the acceptor fluid are removed through the 
sampling arm for analysis to determine the rate and extent of transdermal absorption. After 
removing a probe from the sampling arm, the volume is replaced by fresh medium. Care 
needs to be taken to avoid any air bubbles below the membrane.  
The donor chamber may either be left open or be occluded. Non-occluded conditions permit 
an exchange with the environment, such as evaporation of volatile substances and drying of 
the skin surface. This setup is usually desired for liposome examination for they are 
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supposed to be better absorbed due to the water gradient across the skin [54]. In contrast, a 
tight occlusion of the skin surface may lead to excessive skin hydration. This effect is 
sometimes desired to achieve a higher drug absorption, e.g. in Transdermal Therapeutic 
Systems (TTS).  
One problem often encountered with this setup is the realization of sink conditions for low 
soluble substances in aqueous media. For such purposes organic solvents, non-ionic 
surfactants, proteins (BSA) or cyclodextrines are sometimes added as solubility enhancers 
[28]. However, it is important to keep in mind that these additives may have a severe impact 
on skin integrity and barrier function, and therefore interpretation of such data has to be 
done very cautiously.  
Franz diffusion cell experiments can also be adapted to penetration experiments as the skin 
can be segmented after incubation in the Franz diffusion cell [32].  
All skin absorption experiments presented in this thesis were performed with Franz diffusion 
cells.  
 
 
Figure 1-3 Franz Diffusion Cell. Images courtesy of Mr. Puetz, Saarland University. 
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Flow-through diffusion cell 
In the flow-through diffusion cell the fresh buffer is continuously pumped through the 
acceptor chamber [55]. Thus, sink conditions can be maintained more easily throughout the 
whole experimental period. This is important if the absorption rate of the substance is high 
and/or the solubility in the acceptor phase is low. A minimum flow-rate is necessary to 
ensure thorough mixing, to remove the absorbed material rapidly, and to minimize unstirred 
layers [56]. For the majority of substances a higher flow-rate does not change the absorption 
characteristics, with the exception of very low soluble substances, such as e.g. testosterone. 
Furthermore, the skin viability is prolonged [55,57,58] due to constant replacement of the 
physiological acceptor solution. Therefore, possible metabolism in the skin can be 
investigated.  
Contrastingly, the constant flow of fresh donor below the skin leads to an increased 
partitioning of hydrophobic compounds from the skin to the acceptor solution. This may 
change skin properties und therefore influence the permeation process.  
1.2.3 In vitro skin penetration model 
Saarbruecken penetration model 
The Saarbruecken penetration model was developed to study the rate and extent of drug 
penetration into the different skin layers [32,59]. Here, in contrast to the Franz diffusion cell 
and the flow-through cell, the skin for itself acts as the acceptor for the penetrating drug. 
The major advantage of this set-up is that excessive hydration of the skin can be avoided. In 
addition, possible changes of the skin’s quality and barrier function caused by the acceptor 
medium are prevented. Depending on the drug, the incubation time should be limited to the 
time until the drug reaches the lowermost layer of the skin. After this point, sink conditions 
are not further maintained, resulting in complicated kinetics which are difficult to interpret. 
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1.3 Finite dose  
1.3.1 Comparison finite and infinite dosing 
In contrast to infinite dose experiments with an infinitely large donor and therefore 
negligible changes in the donor concentration over the whole incubation time (less than 
10%), in the finite dose regime only a limited amount of the donor formulation is applied to 
the skin surface. The application of a finite dose best resembles the in vivo patient exposure 
situation when applying e.g. an ointment. Due to the small applied formulation volume the 
donor concentration will significantly decrease during the time course of the experiment 
(donor depletion). The nature of finite dose experiments allows for observation of special 
effects, like the influence of evaporation of excipients [60]. These effects are not visible in 
infinite dose experiments.  
Per definition in OECD guideline 428 [27] and guidance document 28 [28], finite dose skin 
absorption experiments are characterized by the application of ≤ 10 µl/cm² of a liquid 
formulation to the skin. For semisolid and solid substances, values range between 1 and 
10 mg/cm² [27-29]. Although most publications dealing with finite dose follow this definition 
[61-71], other values are also reported [72-79].   
This thesis follows the definition of the OECD guidelines [27,28].  
1.3.2 Challenges associated with experimental finite dose setup 
In normal in vivo patient regime, the semisolid formulation is applied to the skin and 
distributed by a finger or hand. However, for in vitro finite dose experiments, an adaptation 
of this method is required to ensure the application of a defined drug amount to the skin 
and a homogeneous drug distribution. Therefore, this chapter gives a short overview about 
experimental challenges.  
 
Experimental incubation time 
As shown above, the definition of finite dose experiments varies in different papers. To 
harmonize the results, a generally accepted definition would be the aim. However, a general 
definition for all substances is difficult since finite dose characteristic kinetics, e.g. donor 
depletion, may be obtained only after long exposure times for some chemicals and may not 
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be reached during the course of the experiment. Thus, the incubation time needs to be 
adapted to the experimental setup, e.g. the drug and the vehicle.  
 
Application and distribution of the drug 
The application of a clearly defined amount of drug to the skin is essential for the correct 
evaluation of the experiments, e.g. for calculation of the mass balance.  
Furthermore, a homogeneous drug distribution over the entire incubation area is important. 
If a homogeneous distribution can not be ensured, the variation between the experiments 
may increase [72]. It is quite difficult to spread the donor formulation evenly over the 
incubation area since only a very small volume of the donor formulation is applied to the 
skin. 
To ensure both requirements are fulfilled, semisolid formulations are mostly applied and 
distributed manually, employing metal [80], glass [65,81] or plastic [82] spatulas [83], or a 
glass rod [64,70,84-87]. 
As it is crucial to know the exact applied dose in finite dose experiments, the amount of drug 
remaining on the mechanical distribution device, unapplied to the skin, is essential. Thus, the 
application device needs to be analyzed for the exact amount of applied formulation, which 
can be determined by weight [65,70,81,84,85] or extraction of the remaining formulation 
from the application device [64].  
For liquid formulations the weight determination is delicate, as evaporation might affect the 
measurement. Thus, a defined volume of the liquid formulation is usually applied with a 
positive displacement pipette [62,63,88] or a micro syringe [84]. For standardization, for 
each experiment a reference volume can be pipetted, and the drug amount analyzed.  
Liquid formulations are often distributed over the skin surface by the positive displacement 
pipette used for application [62,88]. Other methods are placing a teflon disc onto the 
formulation to increase spreading [50] or using an appliance, e.g. a micro centrifuge tube 
[11] or the rubber tip of a 1 ml syringe plunger [63] or an inoculating loop [71] for 
distribution.  
Further methods, such as massage of the skin lead to uniform distribution of the 
formulation, but the mechanical stress might have an influence on the absorption behaviour. 
In some cases, e.g. for nanoparticles, this might even be desired, leading to higher 
concentrations in hair follicles after massage of the skin due to a pumping mechanism [13].  
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As the SC is a lipophilic layer, the distribution of lipophilic formulations over the surface may 
be more homogeneous than for hydrophilic formulations. Also, the distribution can be 
increased by adding an emulsifier to the formulation. However, both methods may change 
the absorption characteristics of the substance under investigation.  
Ideally, the application method should result in a homogeneous layer of the drug 
formulation over the whole incubation area. The influence of inhomogeneous donor 
distribution over the skin surface on permeation is investigated further in chapter 4. 
 
Mass balance 
Due to the limited amount of drug applied to the skin, a mass balance is required for each 
experiment to ensure the recovery of the entire drug. A reproducible and quantitative 
recovery is indispensable for correct evaluation of the data. In the OECD guidelines [27,28], it 
is stated that 100±10% of the drug should be recovered after the experiment. In another 
guideline the range was broadened to 100±15% [29]. To achieve these limits, not only the 
skin and the surface of the skin need to be analyzed, but also all instruments/devices in 
contact with the drug, e.g. the diffusion cell. Furthermore, a low limit of quantification for 
the substance under investigation is required.  
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1.3.3 Principles of finite dose kinetics 
The absorption process of a substance into or through the skin is usually assumed to be a 
passive process, controlled by diffusion. Thus, both infinite dose and finite dose experiments 
can be described by Fick’s laws.   
Diffusion across a homogeneous membrane between donor and acceptor compartment can 
be described by Fick’s first law [89], treating the skin layer as a pseudo-homogeneous 
membrane  
  
x
CDJ
∂
∂
−=        (Equation 1-1)  
with the flux J [µg/cm²*h] as the transport rate per time of a compound, the concentration 
gradient ∂C/∂x, and the diffusion coefficient D. Assuming that sink conditions apply, the 
concentration inside the membrane is zero at the beginning of incubation. Furthermore, at 
x=0 the concentration is in local equilibrium with the vehicle.  
To simulate the varying concentration of a drug within the membrane, Fick’s second law [89] 
can be employed.  
  
²x
D²D
t
C
∂
∂
=
∂
∂
       (Equation 1-2)  
This equation is derived from the combination of a differential mass balance with Fick’s first 
law. This equation assumes that the compound neither binds, nor is metabolized, and that 
the barrier properties remain constant over time and position.  
 
The maximum absorption rate to the skin may be reached for some time during finite dose 
experiments, but is not maintained [28], which is due to the depletion of drug in the donor 
compartment. Under finite dose conditions the donor decrease is more than 10% of the 
initial concentration [4]. An effect of this donor depletion can only be seen after some time 
in the absorption profile when the flux decreases over time. Thus, a ‘quasi-steady-state’ at 
the beginning of the incubation might be reached for a short time.  
In general, the absorption process can be divided into three main phases as described in 
[90]: In the lag-phase the drug diffuses into the skin and slowly fills up the different skin 
layers. In the following rising phase some drug enters the acceptor compartment and rises 
with time. Afterwards, in the falling phase the strongly decreased drug amount in the donor 
compartment (donor depletion) leads to a decreasing flux across the skin.  
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• Permeation 
Permeation experiments often employ a thinner skin membrane than penetration 
experiments, e.g. heat-separated epidermis. Thus, the drug enters the acceptor faster. The 
accumulation in the acceptor is measured at different sampling intervals.  
When comparing the permeation profile of a finite dose experiment to an infinite dose 
experiment, at the early stage, the finite dose permeation profile resembles the infinite dose 
profile (fig. 1-4 A). However, after a certain time, the infinite dose experiments reach a 
steady-state, characterized by a constant flux Jss of the drug through the membrane (fig. 1-4 
B). This is not the case in finite dose experiments, where after reaching donor depletion the 
absorption rate (flux) decreases and the cumulative drug amount in the acceptor approaches 
a maximum.  
 
 
Figure 1-4 Permeation kinetics of infinite and finite dose. A: Cumulative permeated amount over time. B: 
Flux over time. Modified from [4].  
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• Penetration 
In penetration experiments, usually full-thickness skin is employed and the absorption of the 
drug into the different skin layers is investigated. For analysis of the drug distribution within 
the different layers, the skin is segmented and the drug concentration in the different skin 
sections is calculated. The segmentation of the skin is usually performed by first tape-
stripping the SC and then horizontal cutting of the deeper skin layers (DSL). Following 
quantification of the drug amount in each sample, the drug concentration normalized to the 
respective skin volume can be determined for a certain skin depth. From analysis of samples 
from different skin depths, concentration depth profiles can be established (fig. 1-5). For 
more information see chapter 10 Appendix. 
Infinite dose concentration depth profiles at all times have a higher concentration at the 
outer SC layers compared to the innermost SC layers. The concentration of the drug in the SC 
slowly increases with increasing incubation time, thus changing the shape of the profile from 
an exponential decay to a linear regression over depth at steady-state (fig. 1-5 A).  
For finite dose experiments, the concentration depth profile at the first time point is similar 
to the infinite dose scheme. Then, the drug concentration in the deeper SC layers increases 
over time, still similar to infinite dose, however with the concentration at the outermost SC 
part not increasing. Afterwards, the concentration in the outer SC layers decreases as the 
donor depletes, the shape of the curve slowly turning from exponential decay to linear but 
flat profiles at the longest incubation times (fig. 1-5 B).  
 
 
Figure 1-5 Concentration depth profiles in the SC for different incubation times. A: Infinite dose. B: Finite 
dose. Example data calculated with DSkin (developed by Dominik Selzer, Master Thesis).  
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Another information that can be obtained from penetration studies is the cumulative drug 
amount in each skin layer, e.g. in the SC or the DSL. This data can be plotted against the time 
resulting in mass profiles of the drug in the different compartments. From these results, 
information about certain kinetic characteristics can be analyzed, e.g. the formation of a 
drug reservoir in a skin layer.  
For infinite dose experiments, the drug amount in the SC approaches a maximum 
representing the steady-state and thus saturation of the drug in the respective layer (fig. 1-6, 
dashed line). The data can be fitted to Michaelis-Menten-kinetics [32], which is applicable to 
saturable processes. With this method the drug amount during steady-state in the SC can be 
determined for infinite dose, as well as the time until half of the maximum drug amount is 
reached.  
 
Figure 1-6 Schematic accumulation of a model drug in the SC for finite dose (solid line) and infinite dose 
(dashed line) scenario. Not drawn to scale.  
 
In contrast to infinite dose experiments, the donor depletes over time in the finite dose 
scenario (fig. 1-7 Donor). The drug amount in the SC increases at the beginning, but after 
donor depletion the rate of absorption of drug to the SC is decreased and the drug amount 
in the SC decreases over time (fig. 1-7 SC). Thus, the amount of drug in the SC will continue 
to diffuse into the DSL, whereas this layer is not filled up as strongly as at the beginning from 
the donor side (fig. 1-7 DSL). The DSL is then still constantly filled up with drug, and drug 
enters the acceptor. At long incubation times the drug amount in the DSL will decrease, too. 
The acceptor is constantly filled up over time, reaching a maximum (fig. 1-7 Acceptor).  
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Figure 1-7  Schematic accumulation of a model drug after finite dose application in the different skin 
compartments. Not drawn to scale. Establishing of the profiles with the help of Dominik 
Selzer.  
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1.4 Modelling of skin absorption 
Since skin absorption experiments are time consuming and expensive, easier and faster ways 
of predicting the absorption kinetics of a drug to the skin are of great interest. With the help 
of mathematical calculations, valuable information can be gained about the absorption of 
the substance under investigation.  
Most mathematical predictions require physicochemical parameters of the substance, e.g. 
the molecular weight MW and partition coefficient log Ko/w [91]. In general, smaller 
substances penetrate the SC faster than larger substances and the absorption of compounds 
above 500 Da rapidly decreases with increasing size [92].  
The partition coefficient has a major influence on skin absorption due to the lipophilic 
character of the SC, leading to low partitioning of hydrophilic compounds into this layer. 
Thus, lower concentrations are available for further partitioning into the hydrophilic viable 
skin layers. On the other hand, highly lipophilic compounds partition easily into the SC, but 
only reluctantly to the viable skin layers. Thus, systemic absorption is also hindered. A value 
of 1 to 3 for log Ko/w has been proposed to indicate good skin absorption [93].  
A factor, which has recently been investigated, is the binding property of a drug to proteins 
in the corneocytes [20,94], which would decrease the speed and amount of drug absorption 
[95]. Furthermore, dependent on the drug the ionization state may change the absorption of 
the compound [96]. Due to the lipophilic nature of the SC, most compounds are better 
absorbed in the non-ionized form, e.g. flufenamic acid. The Ko/w for ionisable compounds can 
be corrected with respect to the pH of the buffer applied, resulting in the log D value [94].  
In addition to the substance characteristics, the vehicle also has a great influence on the 
absorption rate to the skin [97,98]. Lipophilic ointments for example have an occlusive effect 
on the skin and might increase the absorption of certain substances. This is due to the 
prevention of water evaporation from the SC, thus swelling the tissue [99]. The same effect 
can be found in a diffusion cell with an aqueous acceptor and donor formulation. In fully 
hydrated SC, for most substances the water diffusivity in the corneocytes is increased [100].  
For predicting skin absorption of a substance, the DSL is usually regarded as an unstirred 
aqueous layer for simplification and the acceptor as perfect sink to simplify analysis.  
One problem associated with mathematical predictions of substance permeability is the 
determination of the input factors. Even a small change in the parameters might lead to 
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significant changes in the results. Thus, experimental protocols need to be carefully 
evaluated and validated.  
 
Analysis of experimental data 
• Permeation experiments 
The data of the cumulative amount from permeation experiments is usually plotted versus 
the time and certain parameters can be determined from this graph. From permeation 
experiments, the cumulative permeated drug amount Qt through the membrane can be 
determined by the following equation:  
  
l
tcADQt
⋅⋅⋅
=
∆
       (Equation 1-3) 
with the incubation area A, the concentration gradient across the membrane 21 ccc −=∆ , a 
time period t, and the membrane thickness l. For the infinite dose case, the concentration 
difference across the membrane Δc is constant.  
For infinite dose experiments, Jss can be determined by simple linear regression from the 
graph, or can be calculated using Fick’s first law. The steady-state flux can be estimated by: 
l
cDJss
⋅
=        (Equation 1-4) 
Here, c is the concentration in the membrane, which is related to the easily obtainable 
concentration in the donor cdon and the partition coefficient between donor and membrane 
Km: donm cKc ⋅= . When Km is not available and the vehicle consists of an aqueous donor 
phase, often estimates using Ko/w are employed. The boundary conditions for an infinite 
donor and perfect sink are: c=∞ at x=0 and c=0 at x=l.  
  
l
cKDJ donmss
⋅⋅
=        (Equation 1-5)  
Furthermore, the lag time tlag can be determined by extrapolation of the linear part of the 
graph to the x-axis. Mathematically, the lag time can be determined as follows according to 
[89]: 
  
D
lt lag 6
2
=         (Equation 1-6)  
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The permeability coefficient kp allows for normalizing the steady-state flux to the applied 
donor concentration in the vehicle cv. Thus, formulations with different drug concentrations 
can be compared:  
  
v
ssm
p c
J
l
KDk =⋅=       (Equation 1-7)  
 
For finite dose, steady-state is not established, thus steady-state parameters like Jss and kp 
can not be calculated. Instead, the momentary flux can be estimated by fitting to a non-
steady-state solution of Fick’s law, and the peak flux value and the time to reach peak flux 
can be determined (fig. 1-4 B) [101].  
A transfer coefficient kt as the ratio of the instantaneous flux Ji normalized to the specific 
dose can be determined according to [102]:  
dosespecific
Jk it
100⋅
=       (Equation 1-8) 
 
• Penetration experiments 
From penetration experiments concentration depth profiles can be obtained, which give 
information about the distribution of the drugs within the different skin layers (fig. 1-5). To 
be able to calculate concentration depth profiles, the drug concentration in each skin pool is 
required, as well as the volume of the skin layer removed, and the depth inside the skin. For 
better understanding, the calculation of concentration depth profiles with the help of 
infrared densitometry is thoroughly explained in chapter 10 Appendix. In short, the 
normalized drug concentration within the different skin layers is determined over depth.  
Furthermore, the cumulative drug amount in the skin layers, e.g. the SC can be calculated for 
the different incubation times (fig. 1-6, fig. 1-7). Thus, comparison between different 
formulations and anatomical sites is possible. Also, saturation effects in the skin layers can 
be investigated, e.g. with Michaelis-Menten kinetics according to [32]: 
incmax/
incmax
act tt
tm
m
+
⋅
=
2
      (Equation 1-9) 
With mmax as the maximum drug amount present in the skin layer after establishment of the 
steady-state, tmax/2 as the time until half of the maximum drug amount in the skin layer is 
reached, tinc as the incubation time, and mact as the actual drug amount at tinc.  
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Several approaches of calculating the skin absorption or permeability of different substances 
are available. The three most common types of mathematical models are presented in the 
following chapters. 
1.4.1 Quantitative structure activity relationship (QSAR) models 
Quantitative structure activity relationship (QSAR) models employ the substance’s 
physicochemical properties to estimate the permeability of a substance to the skin. The 
input parameters can be calculated from the molecular structure or derived from 
experiments. QSARs are based on the assumption that the permeability of a substance can 
be calculated by its physicochemical properties only and completely neglect the structure of 
the skin.  
The most important (and most often applied) properties employed are the molecular weight 
MW and the octanol/water partition coefficient log Ko/w. As molecular weight and volume 
are related by a factor of ~0.9 g/ml, both parameters can be used in the models [103].  
The simplest models solely employ log Ko/w and MW for prediction of the absorption of a 
substance. The most commonly used model was developed by Potts and Guy [91]:  
  MWβKlogfDlogklog ''w/op ⋅−⋅+





∂
=
0
   (Equation 1-10) 
with D
0
 as the diffusivity of a hypothetical molecule with a MW of zero, ∂ as diffusion path 
length, f a coefficient to correct for SC partition coefficient, and β’’ as another coefficient to 
correct for MW. Assuming log D
0
/∂ as constant and including a database of permeability of 
more than 90 chemicals [104] a more detailed equation was developed, being able to 
explain around 70% of the variability of the experimental data.  
  MW.Klog..klog w/op ⋅−⋅+−= 0061071036    (Equation 1-11) 
Since then, many adaptations have been made to this model, like applying the models to 
different data sets [105]. Further physicochemical characteristics of the chemicals were 
included, like hydrogen bonding [106,107], and in other models, MW was replaced by MW
x
, 
where an exponent x was introduced [105].  
With QSAR models, information about the permeability of a substance can easily be 
estimated without extensive computational effort. It needs to be taken into account, 
however, that not for all substances the permeability can be correctly estimated and that 
they do not allow for the prediction of the absorption with time. Thus, they are limited to 
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the steady-state and therefore only suitable for infinite dose conditions. Furthermore, they 
do not consider the influence of the vehicle or other physicochemical parameters, limiting 
the informative value of the QSAR results.  
1.4.2 Pharmacokinetic models 
Pharmacokinetic (PK) models describe the skin layers as well-stirred compartments with a 
uniform drug concentration in each compartment. The transport between the different 
compartments is modelled with first order rate constants. Due to these simplifications, the 
computing time is strongly reduced compared to more complex models, e.g. diffusion 
models. 
The simplest compartmental model for skin absorption consists of solely one skin 
compartment, sandwiched between a donor compartment and an acceptor compartment 
[78,108]. The latter one may represent the blood and thus systemic distribution and 
elimination. The number of compartments can also be increased, dividing the skin into the 
SC and the DSL [78,108,109]. The two compartment model is advanced because the actual 
conditions can be better fitted/simulated than in a homogeneous skin compartment with 
identical properties. Fig. 1-8 shows the schematic structure of a two compartment PK model 
with the SC and the DSL as the two skin compartments.  
Also, three compartmental PK models have been developed, further segmenting the viable 
skin layers [78]. Even more compartments are possible, dividing the different skin layers into 
a certain number of compartments, thus being able to fit the different concentrations within 
one skin layer [78]. Besides, the advantage over diffusion models has not yet been 
evaluated.  
In general, two compartment models are assumed to be best suited to make the 
compromise of accuracy and complexity [78].  
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Figure 1-8 Schematic diagram of a two-compartment PK model with the different compartments (V: 
vehicle, SC: stratum corneum, DSL: deeper skin layers (viable epidermis + dermis), A: 
acceptor/blood) and the rate constants 
 
For a one compartmental PK model the differential mass balance of chemical can be 
determined as: 
  bskinskinv
skin
skin CkCkCkCkdt
Cd
V 2211 −− +−−=   (Equation 1-12) 
according to [103,108] with skinC as the position averaged concentration in the skin 
compartment. For a two-compartment model the position averaged concentration in the 
viable skin layers veC  is included: 
  veSCSCv
SC
sc CkCkCkCkdt
Cd
V 2211 −− +−−=   (Equation 1-13) 
  bveveSC
ve
ve CkCkCkCkdt
Cd
V 3322 −− +−−=   (Equation 1-14) 
In general, pharmacokinetic models without rate constants as input parameters only fit 
experimental mass profiles. The rate constants describing drug transport may however be 
related to physicochemical parameters of the drug or to anatomical characteristics 
[109,110]. However, a correlation between rate constants and physicochemical or 
anatomical parameters is difficult.  
PK models are well suited to describe the finite dose scenario as mass profiles.  
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1.4.3 Diffusion models 
In contrast to QSAR and pharmacokinetic models, diffusion models not only employ 
physicochemical parameters of the substance for their calculations, but they also take into 
account the anatomical structure of the skin. Thus, the models usually reproduce the 
geometry of the skin and the diffusion characteristics in the different skin layers, introducing 
more realistic parameters to the calculations. For example, the SC is generally regarded as a 
more lipophilic layer with other diffusion properties than the viable skin layers.  
Diffusion models are based on the principle that transport mainly occurs via passive 
diffusion. Thus, the degree of diffusion is determined by the concentration gradient and 
diffusion laws can be applied. Applying Fick’s first law, diffusion models are able to simulate 
the steady-state characteristics of a substance, e.g. the lag-time, the flux, or the 
permeability. Fick’s second law is solved in time and space dimensions to simulate the 
diffusion process in temporal and local resolution.  
In contrast to steady-state models, non-steady-state models also allow for predicting 
transient processes like the changes of drug concentration in the different skin layers or the 
acceptor at certain time points of interest. Also, non-steady-state models are best capable of 
obtaining information about the mechanisms of skin absorption.  
Diffusion of the substance under investigation can be simulated in varying degrees of 
complexity. One dimensional (1D) diffusion models assume the drug transport solely in one 
direction, strongly simplifying the absorption process. In these models, the SC is modelled as 
a homogeneous membrane, assuming that the transport is constant throughout the 
membrane. Some models only include the lipid phase as diffusion pathway through the SC, 
due to higher diffusion rates in this phase. 1D models have short computing times, but are 
not able to account for the heterogeneous structure of the SC with the different possible 
diffusion pathways through corneocytes or lipids [60,111,112].  
Two-dimensional (2D) diffusion models include the drug transport in a second spatial 
dimension. Here, the brick and mortar structure of the SC is simulated, with corneocytes 
embedded in the lipid matrix [16,19]. Other approaches assume not only two distinct 
compartments in the SC, but also include a detailed resolution of the lipid channel [113,114].  
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Homogenized models simulate the SC as a homogeneous membrane, but include the 
different diffusion parameters of the corneocytes and lipids in the three different spatial 
directions [115,116].  
The diffusion and partition parameters for diffusion models can be calculated or determined 
experimentally. In the past, corneocytes have often been regarded as impermeable [17]. 
Thus, diffusion was solely simulated in the lipid phase with the diffusion coefficient Dlip. As 
determined with fluorescence recovery after photo bleaching (FRAP) measurements, Dlip is 
generally inversely related to molecular weight [117].  
For heterogeneous models, the diffusion was modelled along the long, tortuous pathways 
around the corneocytes [16]. The length of the pathways around the corneocytes has been 
evaluated previously [17,118,119], and calculated as multiple times the thickness of the SC. 
Due to the tortuosity of the SC, lateral diffusion is usually regarded faster than transversal 
diffusion [113,120].  
However, recent investigations showed that there is indeed absorption of the drugs into the 
corneocytes, first of all water [20]. This is especially important for hydrophilic compounds, 
which can be dissolved in the water inside the corneocytes and diffuse through the cells. If 
corneocytes are modelled as permeable cells, diffusion parameters in the corneocytes Dcor 
and partitioning between corneocyte and lipid phase Kcor/lip need to be included. Lipophilic 
phase and corneocytes do not, however, contribute to drug absorption to the same degree. 
Therefore, different ratios of Dcor/Dlip and the partitioning between the structures defined as 
corneocyte/lipid partition coefficient Kcor/lip were investigated towards the permeability of 
the drug [16,121].  
Only, if the drug enters the corneocytes and is dissolved, binding to the intercellular keratin 
is possible [122]. Keratin binding has recently been investigated for different drugs, e.g. for 
flufenamic acid (FFA) [18,20], testosterone [20], and other drugs [94].  
Another complicating factor is the varying diffusivity over depth in the SC, which has been 
explained by changing lipid conformational ordering over depth inside the SC [123,124]. 
Also, the water content in the SC changes over depth [125]. The influence of varying 
partitioning and diffusion characteristics over depth has been investigated previously, and 
the partition coefficient was found to have a stronger effect on the predicted flux [126].  
Furthermore, degradation of the desmosomes between the corneocytes leads to a loosening 
between the corneocytes and changed diffusion characteristics. The effect of desquamation 
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on drug absorption with the help of a mathematical model has been investigated 
precedently [127].  
In the case of a heterogeneous SC, the partitioning of the donor to the SC (Ksc/don) of the 
different SC parts has to be included as Klip/don and Kcor/don, too. The first can be estimated 
from b w/oKa ⋅  , where b can range from 0.7 to 0.86 [128-130].  
In most diffusion models the viable skin layers are modelled and the partitioning into this 
layer Klip/DSL and the diffusion in this layer DDSL are included. The viable skin layers are mostly 
regarded as a homogenous, well-stirred layer with constant diffusion parameters. The 
diffusion coefficient in the donor Ddon varies with the vehicle applied.  
 
With the inclusion of many input parameters, different target results can be obtained. In 
most publications, the permeation is modelled and from this the permeability, the lag-time 
or the steady-state flux can be determined. Only few studies however attempt to simulate 
concentration depth profiles of a drug in the skin.  
A 2D diffusion model based on experimentally determined input parameters was previously 
developed in this working group together with the Wittum group in Frankfurt [18,19]. The 
input parameters employed for this model are schematically visualized in fig. 1-9. The 
geometry of the model was adapted from [16], increasing the number of corneocyte layers 
to 16 and adding a DSL compartment. Fickian type diffusion behaviour was assumed. 
This model was able to correctly predict experimentally determined infinite dose 
concentration depth profiles in the SC and the DSL for FFA and caffeine. The big advantage of 
this model was the use of experimentally determined diffusion and partition parameters, 
allowing for more realistic simulations. Up to now, most simulations have not been validated 
by experimental data, which is a big deficit.  
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Figure 1-9 Schematic visualization of the diffusion and partition parameters employed in the 2D diffusion 
model of [19]. Here, the SC is plotted with the corneocytes (cor) and lipid phase (lip). The DSL 
is shown as homogeneous, well-stirred layer. Not drawn to scale and not all corneocyte layers 
are plotted. Adapted from [18].  
 
Finite dose skin absorption experiments are much more complex than infinite dose 
experiments. As finite dose experiments do not reach a steady-state, the diffusion 
parameters change over incubation time. Due to this reason and because of the high 
variability between the experiments, derivation of input parameters from finite dose 
experiments is quite difficult [128]. Therefore, input parameters for predicting the finite 
dose permeation profiles are often derived from infinite dose experiments, which has been 
shown to give reasonable results [128].  
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2 Aim of the thesis 
Skin absorption experiments are of interest for toxicological and therapeutic drug 
evaluation. In this respect, finite dose experiments are even more interesting for skin 
researchers since the application of a finite dose to the skin is much closer to the in vivo 
situation than the application of an infinitely large amount of formulation. However, finite 
dose experiments are difficult to perform and to analyze. Therefore, many studies still only 
regard the infinite dose case when investigating the absorption behaviour of substances to 
the skin. Thus, still plenty of work needs to be done to fully understand finite dose skin 
absorption behaviour.  
Over the past decades, non-experimental methods are gaining importance for predicting the 
experimental results while also reducing lab time and costs, e.g. the use of mathematical 
modelling. This method is very promising due to easy accessible information about the 
absorption behaviour of a substance to the skin. Due to the high sensitivity of the 
mathematical methods to input parameters, it is essential to employ these parameters as 
accurate as possible. Input parameters may be calculated by models based on 
physicochemical properties of the substances or determined experimentally. Especially, if 
experimental data is addressed, a full validation is needed to minimize data error.  
 
Therefore, this thesis focuses on the evaluation of skin absorption experiments and the 
improvement of experimental data for comparison with mathematical modelling. The 
following points are addressed: 
• Improvement of accuracy of concentration depth profiles obtained from tape-
stripping (chapter 3) 
For the horizontal segmentation of the SC in skin penetration experiments usually 
tape-stripping is employed. The drug concentration in the different SC layers can be 
determined from the extracts of the different tape-strips. Tape-stripping is applied in 
many research groups with different methods for determination of the SC depth after 
each strip. As these methods are often not practicable or lack accuracy, a non-
destructive method for SC quantification on tape-strips, infrared densitometry, is 
investigated for its use in vitro. 
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• Evaluation of the influence of the application area of a finite dose on the permeation 
of the drug through heat-separated epidermis (chapter 4) 
For finite dose experiments, usually a uniform donor surface distribution is assumed. 
However, this is difficult to achieve due to the small applied dose and wrinkles in the 
skin. Thus, the influence of the donor surface distribution on the permeation of two 
model drugs is investigated: caffeine and flufenamic acid. For determining the 
application area the donor solutions are stained and a method to address surface 
distribution (coverage) is developed. 
 
• Analysis of finite dose mass profiles over time (chapter 5) and concentration depth 
profiles in SC and DSL (chapter 6) of skin penetration experiments, both 
experimentally and in comparison with mathematical models 
These chapters aim at combining both aspects mentioned above: to properly perform 
finite dose skin penetration experiments, and to compare the experimental data with 
mathematical models. After improvement of the SC quantification on tapes and the 
evaluation of the finite dose setup, these adaptations are included in the 
experimental procedure of finite dose skin penetration experiments. Furthermore, 
the experimental setup is carefully investigated to ensure the thorough separation of 
the different skin compartments.  
The experimental data of mass profiles in the different skin compartments over time 
(chapter 5) are then analyzed with two mathematical models: A pharmacokinetic 
model, and a two dimensional (2D) diffusion model with high geometric resolution.  
The pharmacokinetic model is developed to describe the mass profiles over time in 
all compartments of skin penetration experiments performed in a Franz diffusion cell, 
including the lateral skin part. The latter comprises compressed skin, which during 
incubation has been tightly squeezed between the two parts of the diffusion cell. This 
skin part is usually neglected in skin absorption studies. The pharmacokinetic model 
in our study is a first attempt to also describe the lateral skin part and the drug 
transport to it during incubation (chapter 5).  
Previously, the 2D detailed diffusion model has been developed for predicting 
concentration depth profiles of infinite dose penetration experiments [19]. This 
model was now adapted to finite dose to simulate both mass profiles (chapter 5) and 
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concentration depth profiles (chapter 6). In this context it was investigated, if input 
parameters from infinite dose experiments [18] can also be used for predicting finite 
dosing. 
 
  45 
3 Infrared densitometry: a fast and non-destructive method for 
exact stratum corneum depth calculation for in vitro tape-
stripping  
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3.1 Abstract 
The investigation of drug penetration into the stratum corneum (SC) by tape-stripping 
requires an accurate measure of the amount of SC on each tape-strip in order to determine 
the depth inside the SC. This study applies infrared densitometry (IR-D) to in vitro tape-
stripping using the novel Squame Scan® 850A. The device had recently been shown to 
provide accurate measurements of the SC depth for tape-stripping in vivo. Furthermore, the 
suitability of IR-D for determining the endpoint of tape-stripping, i.e. complete SC removal 
was tested. The SC depth was computed from the IR-D data of sequential tape-strips and 
compared to the results of a protein assay as gold-standard. IR-D provided accurate depth 
results both for freshly excised skin and for skin stored frozen for up to three months. In 
addition, the lower limit of quantification (LLOQ) of IR-D indicates the complete removal of 
the SC (less than 5% of the total SC remaining) and can be used for adjusting the number of 
tapes applied in situ. Therefore, IR-D is an accurate, fast and non-destructive method for SC 
depth determination.  
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3.2 Introduction 
Recently, studying skin absorption has gained a high interest not only for drug 
administration but also for toxicological substance evaluation, a result of the European 
REACH programme (Regulation (EC) No. 1907/2006) [25]. For most molecules, the SC is 
regarded as the rate-determining and hence the most important skin layer. Penetration 
experiments are performed to evaluate whether and to what extent a drug can invade the 
SC. This can be done by tape-stripping, where the SC is divided into sections parallel to the 
skin surface. By analyzing tapes from different depths inside the SC, information about the 
drug distribution within the SC can be gained. To generate correct concentration depth 
profiles, however, two parameters need to be exactly known. These are 1) the total 
thickness of the SC and 2) the exact depth inside the SC that is reached after a defined 
number of tape-strips. In addition, an experimental indicator for complete removal of the SC 
is necessary (i.e. when tape-stripping should be stopped). Different approaches have been 
developed to determine both parameters and the end point. 
In vivo, the total SC thickness may be assessed non-invasively from the trans-epidermal 
water loss (TEWL) [24,131]. However, it was shown by Netzlaff et al. that this approach is not 
applicable in vitro [132]. Another more recent method for estimating the SC thickness in vivo 
is the application of confocal Raman microspectroscopy [133]. In vitro, the thickness of the 
complete SC can accurately be determined microscopically from cross-sections of skin 
biopsies.  
The depth inside the SC may be estimated using either mathematical or experimental 
methods. For the mathematical approach, the thickness of SC on each tape-strip is 
determined by simply dividing the total thickness of SC by the number of tapes used in the 
stripping procedure [32]. However the amount of SC removed by tape-stripping is different 
on every tape-strip and for every volunteer [134,135]. An overview of the various 
experimental approaches is given in table 3-1 alongside with their individual sources of 
error. Obviously there is no widely available method that is at the same time fast, non-
destructive, and generally applicable. 
To ascertain complete removal of the SC, several experimental methods may be employed 
[136-138], but their systematic error is unknown. Therefore, it is still common practice to 
apply a more or less arbitrary number of sequential tapes ranging from 20 to as high as 100 
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[18,32,137,139-143]. An instrumental method would need to provide a sufficiently fast read-
out so that on this basis it can be decided in the course of the experiment when to stop 
tape-stripping. 
Recently, infrared densitometry (IR-D) was introduced as a new method for SC quantification 
on tape-strips [142]. Here, a beam of light of 850 nm is directed through a tape-strip 
containing SC and the decrease in light intensity is measured (pseudo-absorption). For tape-
stripping in vivo, the optical absorption on a tape was shown to be linearly proportional to 
the protein content. Furthermore, although the data distribution within different subject 
groups varied, the regression was always very similar and independent of gender, age, skin 
hydration, anatomical site (volar forearm, ventral forearm, and shoulder), and skin pH [142]. 
Based on these promising in vivo results, this method might also be suited to determine the 
SC amount on each tape-strip and the end point for tape-stripping in vitro. 
To evaluate the potential of this new method the following topics will be addressed: At first, 
an abridged in vivo study was performed with D-Squame® tape (i.e. the identical tape as in 
the previous in vivo study on the volar forearm [142]). These experiments proved that this 
method could be reproduced in our lab. In addition, we used the same method with a 
different type of tape: tesa® Film kristall-klar was used in vivo on the volar forearm and 
abdominal skin.  
The main focus of the present study was the evaluation of IR-D, first as a method for 
accurate SC quantification on tape-strips in vitro, and further to calculate the SC depth by 
means of these values. Here, in contrast to tape-stripping in vivo, freezing and storage of the 
skin may change the cohesiveness of the SC. Therefore, we investigated the amount of SC 
removed by stripping with tesa® Film kristall-klar for storage times of up to three months. 
The results of the IR-D measurements were compared to a standard method for 
quantification of the SC amount on tapes, a BCA-protein quantification assay (bicinchoninic 
acid).  
The second focus of the study was whether IR-D can be used for objective and immediate 
determination of complete SC removal. For this purpose, biopsies were taken after in vitro 
tape-stripping as soon as the lower limit of quantification (LLOQ) of the IR-D instrument was 
reached. Cross-sections were inspected microscopically for remaining SC and the systematic 
error of the method was evaluated. 
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Table 3-1 Overview of common methods used for the determination of SC amount on tape-strips. 
(Pseudo-absorption: decrease of transmitted light due to reflection, diffraction and scattering; 
BCA: bicinchoninic acid) 
 
Method  Sources of Errors  Literature 
gravimetry     
differential 
weighing 
 non-specific weight increase due to sweat, 
lipids, formulation excipients 
 [24,131,144,145] 
optical methods     
protein absorption 
at 278 nm 
 non-specific absorption du to other 
substances at 278 nm 
 [146] 
pseudo-absorption 
at 430 nm 
 non-specific pseudo-absorption due to 
sweat, lipids, formulation excipients, 
absorption due to coloured substances 
 [136,141,145,147] 
Trypan blue 
staining, 
absorption at 
652 nm 
 low sensitivity due to background 
colouring of tapes; low resolution of small 
differences in degree of coverage of the 
tape  
 [148] 
protein quantification   
colorimetric 
quantification of 
NaOH-extractable 
protein by a 
Lowry-, Bradford-, 
or BCA assay 
 destructive, therefore determination of 
depth and concentration of penetrating 
drug on different skin sites; non-specific 
reaction with a wide range of substances, 
e.g. penetrating drugs 
 [142,144,149,150] 
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3.3 Materials and methods 
3.3.1 Chemicals 
The following reagents were used: sodium hydroxide, potassium dihydrogen phosphate and 
potassium chloride (Merck, Darmstadt, Germany), hydrochloric acid (Grüssing, Filsum, 
Germany), sodium hydrogen phosphate dihydrate (Riedel-deHaën/Sigma-Aldrich 
Laborchemikalien, Seelze, Germany), sodium chloride (VWR Prolabo, Leuven, Belgium), 
Ringer solution (Fresenius Kabi, Bad Homburg, Germany), type I-Trypsin, from bovine 
pancreas, and bovine serum albumin (Sigma-Aldrich, Steinheim, Germany). Purified water 
was prepared by a Millipore Synthesis device (Millipore GmbH, Schwalbach, Germany).  
The BCA protein assay kit (BCA Kit, Sigma-Aldrich, Steinheim, Germany) includes reagent A 
(bicinchoninic acid in 0.1 N NaOH with sodium carbonate, sodium tartrate, and sodium 
bicarbonate) and reagent B (4 % (w/v) copper(II) sulphate pentahydrate solution)), which 
were mixed together in a ratio of 50:1 (V:V) according to the manufacturer's instruction.  
Tesa® Film kristall-klar, (t-tape, 33 m x 19 mm, #57330-00000-02, cut to pieces of 
16 x 19 mm) was provided by the tesa AG, Hamburg, Germany. Standard D-Squame® (d-
tape, 22 mm in diameter) was provided by Cuderm Corporation, Dallas, USA.  
3.3.2 Skin 
The in vivo study included seven healthy female Caucasian volunteers (age range 24-50 
years) with no active skin disease in the stripping area. These were tape-stripped on the 
volar forearm and/or the abdomen with two different tape-strip brands (v.i.). The volunteers 
were asked not to apply any cosmetics on the stripping area and to wash the skin with water 
only within the 24 hours prior to the experiment. All volunteers had previously signed 
informed consent forms.  
Human skin for in vitro experiments was obtained from plastic surgery of Caucasian patients 
from the Department of Plastic and Hand Surgery, Caritaskrankenhaus, Lebach, Germany. 
The study included abdominal skin from four female Caucasian patients (age range 31-41 
years) and breast skin from one male donor (30 years). After excision and cleaning the SC 
side with purified water, the subcutaneous fatty tissue was removed with a scalpel. The skin 
was cut into pieces of 10 x 10 cm, wrapped in aluminium foil and stored in impermeable 
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polyethylene bags at -26°C until use. The study was approved by the Ethical Commission of 
Department of Plastic and Hand Surgery, Caritaskrankenhaus, Lebach, Germany.  
Based on a protocol by Kligman et al. [45] SC was prepared as previously described [18]. 
Briefly, skin punches of 25 mm diameter were punched out from frozen skin and the skin 
was put on a filter paper soaked with Ringer solution and allowed to thaw. To accelerate the 
separation procedure of the SC, full thickness skin was first separated into epidermis and 
dermis by immersing the skin punch in purified water of 60°C for two minutes then peeling 
off the epidermis from the dermis by means of forceps. The epidermis was transferred into a 
petri dish, and incubated in a 0.15% trypsin solution in PBS (phosphate-buffered saline, 
composed of 0.2 g potassium chloride, 8.0 g sodium chloride, 1.44 g disodium hydrogen 
phosphate dihydrate, and 0.2 g potassium dihydrogen phosphate to a litre of purified water) 
at 37°C for at least 24 hours until the SC was completely separated from the underlying 
tissue. The SC was washed three times with purified water and after drying it was stored in a 
desiccator filled with silica gel until constant weight.  
3.3.3 In vivo tape-stripping  
In vivo experiments were performed with a small number of volunteers as the suitability of 
this method for in vivo had already been shown. Three female Caucasian volunteers (age 
range 24-50 years) were tape-stripped with d-tape in the middle of the volar forearm 
(minimum distance from wrist and elbow: 5 cm). Four female Caucasian volunteers (age 
range 24-30 years) were tape-stripped with t-tape both on the volar forearm and on the 
abdomen (minimum distance from the navel: 5 cm). Before tape-stripping, the skin was 
cleaned with purified water and allowed to dry for five minutes. 
Tape-stripping with d-tape was performed using the entire adhesive area of the tape of 
22 mm diameter. After placing the first tape on the skin, the contour of the tape was 
outlined on the skin with a permanent marker in order to ensure the use of the same 
stripping area for each following tape.  
For tape-stripping with t-tape a teflon mask with an opening of 15 mm in diameter was 
tightly fixed to the skin with band-aid. Then a tape was placed centrally above the stripping 
area and pressed to the skin with the flat side of forceps to ensure homogeneous pressure. 
Then, the tape was removed with forceps in one swift move. Tape-stripping was performed 
with 20 sequential tapes. 
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3.3.4 In vitro tape-stripping 
In vitro tape-stripping was performed under highly standardized conditions as published 
[32]. In short, a punch biopsy (25 mm diameter) was taken, cleaned with a cotton pad 
soaked with purified water and then blotted dry with a piece of cotton. The skin was 
stretched and fixed on cork disks with needles. A teflon mask with an opening of 15 mm in 
diameter was tightly fixed above the skin in order to restrict the stripping area. Then, a tape 
was placed centrally over the stripping area. After applying a weight of 2 kg for ten seconds, 
the tape was removed in one rapid move. Tape-stripping was performed with 20 sequential 
tapes.  
The in vitro study included the excised abdominal skin of four female donors and breast skin 
of one male donor. Tape-stripping was performed directly after excision (“fresh skin”) and 
repeatedly after one week, one month and after three months (“frozen skin”). For 
experiments after storage of the skin, punch biopsies of the same size were taken from the 
frozen skin and put on a filter paper soaked with Ringer solution to thaw. Care was taken to 
strictly avoid repeated freezing and thawing of skin pieces when taking out skin punches. At 
each time point and for each donor, tape-stripping experiments were performed on two skin 
punches and the amount of adherent SC was determined by IR-D and BCA assay. The SC 
amount was translated into the SC depth as explained in section 3.3.10 and chapter 10 
Appendix. 
3.3.5 Infrared densitometry (IR-D) 
IR-D is based on the determination of the pseudo-absorption of a sample, e.g. a tape-strip. 
For tape-strips, this can be due to the tape itself and additional items on the surface of the 
tape, e.g. SC. The IR-densitometer Squame Scan® 850A (Heiland electronic GmbH, Wetzlar, 
Germany) was designed to measure the optical absorption of tape-strips and thus to 
indirectly determine the SC amount on the tape [142].  
The instrument produces a circular beam of light (λ = 850 nm) that is directed through the 
tape-strip containing SC and the decrease in light intensity (in % of the initial intensity) is 
measured over an area of 13 mm in diameter. The large measured area is a big advantage, as 
inhomogeneities in corneocyte distribution on the tape are balanced. In contrast to 
measurements at 430 nm (see table 3-1), at a measuring wavelength of 850 nm errors due 
to molecular absorption are practically irrelevant and thermal denaturation is prevented. 
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Upon placing the tape-strip under the measuring head, the absorption values are 
immediately displayed on the instrument without destruction of the sample, allowing for 
fast and non-destructive readout of the results. 
Immediately prior to the experiment, the instrument was calibrated by setting the 
absorption of an empty sample holder to 0% absorption. The absorption of an ambient light 
filter provided for calibration by the manufacturer should then return 33.8%. According to 
the manufacturer, linearity of the instrument is given in the range of 0-40% absorption with 
a resolution of 0.1%. None of the analyzed tapes returned absorption values above the linear 
range of 40%. The absorption of an empty tape is subtracted from the signal to correct for 
background noise. The lower limit of quantification (LLOQ) was calculated from the five-fold 
background noise of the empty tape.  
After stripping, all tapes were placed in a sample holder with the adhesive side facing up and 
measured with the IR-densitometer according to [142]. As a constant absorption value is 
reached only after three minutes after stripping, the tapes were always measured after this 
time.  
3.3.6 BCA protein assay  
Immediately after IR-D, the tapes were processed for protein quantification. The tapes were 
transferred into scintillation vials and the protein was extracted with 750 µl 1 N sodium 
hydroxide solution for two hours at room temperature. After neutralization with 750 µl 
neutralizing reagent (1 N hydrochloric acid containing 3.3 mM Na2HPO4 and KH2PO4), the 
extract was homogenized by shaking thoroughly. From each sample extract 100 µl were 
transferred into a 96-well plate and 200 µl of BCA reagent were added. The samples were 
incubated at 37°C for 30 min and the UV absorption was measured at λ = 550 nm using a 
UV/Vis plate reader (Tecan, Crailsheim, Germany).  
Standards used for calibration were BSA as model protein and SC extract. The SC extract was 
prepared as follows. An accurately weighed piece of dried SC was placed in a scintillation vial 
and 1 ml 1 N sodium hydroxide was added. The vial was exposed to ultrasound for 15 min 
and then proteins were extracted for 24 hours at room temperature on an orbital shaker. 
Afterwards, the extract was again sonicated for 15 min. After neutralization with the 
neutralizing agent, the extract was filtered (Chromafil® GF/PT – 45/25, Macherey-Nagel, 
Düren, Germany).  
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External standards from SC were prepared in the range of 0.5 µg to 50 µg per well. The SC 
extract was always prepared from the same donor as the tested skin to avoid inter-individual 
variations. This was not possible for fresh skin, because the preparation of SC extract takes 
at least four days. Therefore, BSA was used as a substitute. BSA standards were prepared in 
the range of 0.25 µg to 20 µg per well. A mixture of equal parts of 1 N sodium hydroxide and 
the neutralizing agent was used as a solvent. An identical mixture containing no BSA or SC 
extract served as negative control and for evaluation of background noise. The lower limit of 
quantification (LLOQ) was calculated from the five-fold background noise. 
3.3.7 Influence of disinfectants on BCA assay 
To exclude an influence of the disinfectants on the BCA assay, typical disinfectants 
commonly used during surgery, Braunoderm® and Octenisept®, were tested as substrates in 
the assay. Different dilutions of the disinfectants were prepared in the concentration range 
5 µg/ml to the undiluted disinfectant (1 g/ml). From each of the twelve dilutions 100 µl were 
transferred into a 96-well plate and 200 µl of the BCA reagent were added. Thus, the mass of 
the disinfectants ranged from 0.5 µg to 100 mg per well. As reference and for preparing the 
dilutions of the disinfectants, 1 N sodium hydroxide and neutralizing reagent in a ratio of 1:1 
(V/V) was used. The samples were incubated at 37°C for 30 minutes. Afterwards, the UV 
absorption was measured at λ = 550 nm using a UV/Vis plate reader.  
3.3.8 Determination of SC thickness  
To determine the thickness of the total SC skin biopsies (4 mm diameter) were taken from 
intact frozen abdominal skin. Cross-sections with a thickness of 8 µm were cut with a 
cryomicrotome (Slee, Mainz, Germany) and transferred to microscopic slides. The cross-
sections were dyed with haematoxylin (Carl Roth GmbH & Co KG, Karlsruhe, Germany) and 
inspected with a light microscope at 400 x magnification (Leica, Wetzlar, Germany). 
Microscopic pictures were taken with a camera (Jenoptik, Jena, Germany) and analyzed with 
a software (Carl Zeiss Axio Vision Rel. 4.7) using a graduated scale bar with a resolution of 
0.13 µm/pixel. The mean total SC thickness was determined from measurements at ten 
different spots on the pictures.  
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3.3.9 Determination of SC remaining on the skin after tape-stripping 
The degree of SC removal was determined with a skin biopsy from skin that had been tape-
stripped until the LLOQ of the IR-D had been reached. Pictures of the cross-section were 
taken at 200 x magnification with a resolution of 0.25 µm/pixel and the area of the 
remaining SC was determined over the entire length of the biopsy (i.e. 2.1 to 3.1 mm, note 
that this value is less than the diameter of the biopsy of 4 mm as it is difficult to organize the 
entire biopsy on the microscopic slide without damage). The same procedure was repeated 
for non-stripped SC and the ratio of both areas was calculated. 
3.3.10 Determination of cumulative depth inside the SC 
The cumulative depth inside the SC was determined from the cumulative absorption values 
of IR-D or the SC amount determined by the BCA assay, as published previously 
[137,139,147]. 
  ∑∑
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Here di is the depth reached inside the SC after i tape-strips and dtot is the total SC thickness, 
which has been determined microscopically; x is the absorption measured by IR-D corrected 
for background noise (empty tape) or the protein amount determined by the BCA assay, and 
nmax is the total number of tapes (20).  
3.3.11 Statistics 
Linear regression analysis and determination of confidence intervals were performed by 
Sigma Plot 8.0. Mean values and standard deviations were determined using Microsoft 
Office Excel 2003.  
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3.4 Results 
3.4.1 BCA protein assay 
a) Calibration  
For the calibration of the BCA assay BSA dilutions as well as SC extracts were used as 
standards. Both types of standards provide a linear relationship between the absorption at 
550 nm and the mass of protein, for BSA in the range of 0.25 µg to 20 µg and for SC extract 
in the range of 0.5 µg to 50 µg. A regression analysis was performed over all individual data 
points (for BSA standards these are 30 individually prepared samples for each concentration; 
SC standards were prepared for a total of four skin donors using two to four pieces of SC 
from each donor). Figure 3-1 shows the results of the linear regression analysis and mean 
absorption values (BSA standards mean ± SD for n = 30; SC standards mean for 4 skin donors 
with n = 2-4, scattering of the data is shown via 95% confidence intervals). The SC standards 
prepared from different skins are narrowly distributed (fig. 3-1). The slope of the individual 
SC extracts is between 0.012 and 0.013 and the intercept between 0.021 and 0.025 with 
coefficients of determination between 0.992 and 0.996 (table 3-2). BSA calibration standards 
constantly give approximately a three-fold higher absorption value compared to the SC 
extract. The slope covers the range of 0.033 to 0.045 and the intercept -0.005 to 0.021 with 
coefficients of determination between 0.994 and 0.999 (table 3-2). For d-tape the LLOQ was 
1.45 µg for SC extract and 0.48 µg for BSA. For t-tape the LLOQ was 1.05 µg for SC extract 
and 0.35 µg for BSA (table 3-3). 
 
b) Influence of disinfectants 
Only a very low absorption of 0.005 was found for very high amounts of the disinfectant 
(500 µg per well for Octenisept® and 10 mg per well for Braunoderm®, data not shown). As 
this amount of disinfectant is not reachable under the conditions of the tape-stripping and 
extraction protocol, the influence of the disinfectants on the BCA assay was neglected. 
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Figure 3-1 Absorption of SC extracts of different donors compared to BSA solution at 550 nm in BCA 
assay. Number of calibration series: (skin 1) = 2, (skin 2) = 4, (skin 3) = 2, (skin 4) = 3; (BSA) = 
30. BSA: mean ± SD with 95 % confidence interval, SC extracts: mean with 95 % confidence 
interval.   
  
 
Table 3-2 Data range of linear regression lines for SC extracts of the different donors and of BSA in the 
BCA assay  
Standard Slope [1/µg] Intercept r² 
n (Number of 
calibrations) 
SC extract 1 0.012 – 0.013 0.024 – 0.030 0.996 – 0.997 2 
SC extract 2 0.012 – 0.013 0.020 – 0.029 0.991 – 0.993 4 
SC extract 3 0.011 – 0.012 0.019 – 0.024 0.991 – 0.995 2 
SC extract 4 0.012 – 0.013 0.021 – 0.025 0.991 – 0.993 3 
BSA 0.033 – 0.045 -0.005 – 0.021 0.994 – 0.999 30 
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Table 3-3 Lower limit of quantification (LLOQ) of tapes for IR-D and BCA assay and the percentage of 
tape-strips that were found below these limits 
IR-D BCA assay 
d-tape t-tape 
 
d-tape t-tape 
SC extract BSA SC extract BSA 
LLOQ  8.2% 8.1% 1.45 µg 0.48 µg 1.05 µg 0.35 µg 
Tapes below 
LLOQ in vivo 
0% 
(60 tapes) 
0% 
(80 tapes) 
0%  
(60 tapes) 
0%  
(60 tapes) 
0%  
(40 tapes) 
0%  
(160 tapes)  
Tapes below 
LLOQ in vitro 
n.a. 2.5%  
(720 tapes) 
n.a. n.a. 1.0%  
(210 tapes) 
0%  
(720 tapes) 
 
3.4.2 Infrared densitometry 
The LLOQ for IR-D was calculated from the five-fold standard deviation added to the mean 
background signal of the empty tape. A total of 240 empty t-tapes and 85 empty d-tapes 
were measured. D-tape and t-tape returned a similar LLOQ of 8.2% and 8.1%, respectively 
(table 3-3). 
3.4.3 Tape-stripping in vivo – influence of tape-strip brand and anatomical site 
Our results confirm the findings published by Voegeli et al. [142]. We found a high linear 
correlation (r²=0.632) between the pseudo-absorption measured with IR-D and the mass of 
protein per area of tape-strip measured by a BCA assay for in vivo tape-stripping on the volar 
forearm with d-tape (fig. 3-2 A). A similar correlation between both methods was found for 
tape-stripping in vivo with t-tape both on the volar forearm and on the abdomen (fig. 3-2 B). 
Stripping with d-tape led to closely distributed data points, indicating that similar amounts of 
SC had been removed by each strip independent of the number of tape-strips that had 
already been taken on the respective site (IR-D: approx. 2.5-12.5%; BCA: approx. 2.5-15 
µg/cm
2
). This was different with t-tapes. The amount of SC removed with consecutive tape-
strips varied in a wider range (IR-D: approx. 5-25%; BCA: approx. 2.5-45 µg/cm
2
) (fig. 3-2). 
For both tape-strip brands no sample was below the LLOQ of either IR-D or the BCA assay 
(table 3-3). 
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Figure 3-2 In vivo tape-stripping on the volar forearm (A) with D-Squame® (n = 3) and (B) with tesa® Film 
kristall-klar on both the volar forearm and abdominal skin (n = 4). Each donor was tape-
stripped with 20 sequential tapes on the according anatomical site. Linear regression is 
plotted for both graphs. 
 
3.4.4 Determination of SC thickness in vitro 
The total thickness of the SC ranged from 13.2 µm to 19.2 µm (table 3-4; fig. 3-3 A, C, E), 
which is in accordance with published data [138,151,152]. 
 
Table 3-4  Mean SC thickness of the different donors. 1-4: female abdominal skin, 5*: male breast skin. 
Cross-sections of the skin were analyzed under the light microscope and SC thickness was 
determined by Carl Zeiss Axio Vision Rel. 4.7. using a graduated scale bar. 
Donor Mean thickness of SC ± SD [µm] 
1 13.2 ± 2.65 
2 15.3 ± 2.37 
3 19.2 ± 1.55 
4 17.0 ± 1.99 
5* 18.1 ± 2.27 
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3.4.5 Determination of SC remaining on the skin after tape-stripping in vitro 
Exemplarily the skin of three donors was stripped until the LLOQ of the IR-D was reached. 
The ratio of remaining to total SC area ranged between 3.2 ± 2.5% to 5.0 ± 2.0% for the 
different donors (fig. 3-3 B, D, F). This amount is negligible, therefore in this study it was 
concluded that the complete SC was removed when reaching the LLOQ of the IR-D.  
 
Figure 3-3 Cross-sections of intact skin (A, C, E) and skin after tape-stripping with tesa® Film kristall-klar 
until the lower limit of quantification of IR-D was reached (B, D, F) for skin of three different 
donors.  
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3.4.6 Tape-stripping in vitro – influence of storage time 
The influence of freezing and storing in vitro human abdominal skin on tape-stripping was 
tested for skin of four donors. Tape-stripping results of fresh, unfrozen skin were compared 
to skin stored frozen for one week, one month, and three months. Figure 3-4 shows the 
results of two representative donors displaying two replicates (indicated as circle and 
triangle) of fresh skin and skin stored for three months. The cumulative depth was calculated 
as described in section 3.3.10 from the pseudo-absorption measured with IR-D (open 
symbols) and the protein amount per cm
2
 measured with the BCA assay (filled symbols) and 
was plotted against the tape-strip number.  
Usually the SC was removed in a relatively linear fashion (fig. 3-4, donor 1, 3 month storage; 
donor 2, fresh skin). In a number of cases a plateau was reached which indicates that less 
than 20 sequential tapes were sufficient to approach the SC-epidermal junction. This is 
evident for example in donor 1 with both “fresh”/ non-stored skin punches (18 strips); and 
donor 2 for skin punch A after a storage of three months (14 strips) (fig. 3-4).  
A single time during the study our lab received male breast skin. Therefore this was treated 
separately (data not shown). At all time points except after one month with male breast skin 
less than 20 tapes were needed to remove the SC completely.  
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Figure 3-4 Depth inside the SC reached after sequential tape-strips for abdominal skin of two different 
donors. Tape-stripping was performed in vitro with tesa® Film kristall-klar on fresh, unfrozen 
skin and after storage of the skin at -26°C for three months. Open symbols represent the 
depth calculated with IR-D and filled symbols show the depth calculated with BCA assay. n = 2 
skin punches with 20 sequential tapes for each time point and for every donor. Skin punch A: 
circle, skin punch B: triangle. 
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3.5 Discussion 
3.5.1 Protein substitution for BCA calibration standards 
Different protein quantification assays have been used in the past successfully for the 
determination of the amount of protein removed by tape-stripping and the calculation of 
the SC depth from these values. Ideally, the assay is calibrated with a protein extract 
prepared from the SC of the same skin that is used in the tape-stripping study to avoid 
possible inter-individual differences. As this is not possible in vivo, Dreher et al. suggested 
substituting SC extracts with BSA or γ-globulin [144]. In addition, this avoids the time-
consuming preparation of the SC extract and produces a steeper calibration curve. However, 
when using other proteins than SC extracts for calibration, a direct comparison of tape-
stripping results of different individuals is only possible if differences in protein content, 
protein extraction efficiency, and assay reaction efficiency are negligible. This had not been 
investigated in detail before. Therefore, in the present study we prepared calibration curves 
from SC extracts of different donors and compared them to a calibration curve prepared 
with BSA. Both standards under the present conditions resulted in linear calibration curves 
with quantification limits that are reasonable for protein determination on tapes after tape-
stripping (table 3-3). The slopes and offsets of the calibration curves prepared with SC 
extract from different donors were very similar (table 3-2, fig. 3-1). Therefore, BSA solution 
can be used as a calibration agent for protein quantification and the tape-stripping results of 
different individuals can directly be compared.  
3.5.2 IR-D in vivo versus in vitro 
Recently, IR-D has been introduced as a fast and non-destructive method for the 
quantification of the SC amount for tape-stripping in vivo [142]. The authors reported a 
linear correlation between the pseudo-absorption measured by IR-D and the protein amount 
per area measured by a BCA assay. We could not only reproduce these results in the present 
in vivo study also using D-Squame® (d-tape; fig. 3-2 A), but we could also carry over the 
method to a different tape-strip brand, i.e. tesa® Film kristall-klar (t-tape; fig. 3-2 B). In vivo 
only d-tape removed a similar amount of SC that was independent from the tape-strip 
number and thus would allow for easily estimating the SC depth mathematically. For t-tape, 
this was not always possible.  
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In vitro, in the majority of the profiles the SC was removed linearly, however in some cases 
the curve shape was sigmoidal or a plateau was reached indicating that the SC was 
completely removed already with less than 20 tapes (fig. 3-4). In contrast, this was not 
observed in vivo (data not shown). A potential reason for the discrepancy between in vivo 
and in vitro profiles is the different pressure applied to improve the contact between tape 
and skin surface [149]. 
Moreover, the depth that was reached in vitro with a defined number of tape-strips varied 
even for two different skin punches of the same donor at the same time point (fig. 3-4). 
These results once more emphasize the necessity for using an instrumental method for exact 
quantification of SC on each tape-strip.  
3.5.3 Determination of SC depth 
Regarding the main question of this study, we proved that IR-D does give a similar depth 
inside the SC for all donors and all time points compared to the standard method (BCA 
assay), no matter whether the SC was removed in a linear fashion or not. This shows that 
using this instrumental method to quantify the SC amount on each tape, the SC depth can be 
determined correctly and thus meets the desired aim of being a non-destructive method for 
SC depth determination in vitro. 
3.5.4 Determination of endpoint of complete SC removal 
Concerning the second focus of this study, our results show that IR-D is also well-suited for 
determining the endpoint for complete SC removal as it allows fast in-process monitoring of 
the results (fig. 3-3). Consequently, this method allows for adjusting the total number of 
tape-strips that are performed for a single skin site during the experiment. Thereby, the SC 
depth profiles can be determined more accurately. 
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3.6 Conclusions 
IR-D is a suitable method for the quantification of SC on D-Squame® and tesa® Film kristall-
klar. From the measured pseudo-absorption the cumulative depth inside the SC can be 
calculated with comparable accuracy as from the protein quantification with a BCA assay. IR-
D has two main advantages compared to protein assays such as BCA: The measurement is 
non-destructive so that the depth inside the SC and the drug amount can be determined on 
the identical tape-strip. Furthermore, IR-D can be used for individual and in process 
determination of the total number of tapes that need to be performed for removing the SC 
quantitatively. This is important as this study demonstrated that it is not advisable to work 
with a fixed total number of tape-strips. Therefore, using IR-D for tape-stripping improves 
the quality of skin-concentration-depth-profiles both in vivo and in vitro. 
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4.1 Abstract 
For finite dose skin absorption experiments, a homogeneous donor distribution over the skin 
surface is usually assumed. However, the influence of the surface distribution on skin 
absorption is still unknown. The aim of this study was to evaluate the influence of the 
application area on the permeation of drugs during finite dose skin absorption experiments 
in static Franz diffusion cells. Permeation experiments with stained aqueous drug 
formulations were conducted and the application area was determined by a suitable, 
objective, automated computational approach. In contrast to the maximum incubation area 
possible in the diffusion cell setup, the application area was the area actually in contact with 
the donor at the start of incubation  
The permeation of caffeine is strongly dependent on the application area: The variability 
between the single experiments decreased when including the application area. In addition, 
biopsies from the stained skin area contained significantly more caffeine than biopsies of 
non-stained skin. For the lipophilic flufenamic acid this was not the case. The variability 
highly increased after inclusion of the application area. In contrast to caffeine, flufenamic 
acid distributes fast in the stratum corneum covering the maximal possible diffusion area. 
Thus, a correction of the area is misleading. In summary, depending on the drug’s 
physicochemical characteristics, the real application area may influence skin absorption.  
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4.2 Introduction 
In skin absorption studies infinite dosing is usually employed to evaluate kinetic parameters 
like permeation coefficient [43,105]. However, this does not represent the in vivo situation, 
where usually a finite dose is applied to the skin, and additional effects may influence the 
drug absorption, e.g. evaporation of excipients [60].  
In the OECD guideline 428 [27] and the guidance document 28 [28] finite dose experiments 
are defined as experiments with a maximum applied donor volume of 10 µl/cm² of liquid 
formulations. For semisolid and solid substances, values range from 1 to 10 mg/cm² [27-29].  
The ideal application should result in a homogeneous layer of the drug formulation over the 
whole incubation area. Otherwise, the variation between the experiments will increase [72]. 
However, a homogeneous drug distribution over the whole incubation area is problematic 
due to wrinkles of the skin.  
For creams and ointments even distribution may be confirmed visually, but for uncoloured 
aqueous solutions and gels the distribution can not easily be determined. To this day the 
distribution of a drug over the incubation area has only scarcely been analyzed: In two 
publications, the distribution of a fluorescent model drug in sunscreens over the skin was 
investigated in vivo [153,154] to correlate the results with the sun protection factor. Another 
publication investigated the distribution of the formulation containing a fluorescent dye with 
and without microparticles over the incubation area by in vivo laser scanning microscopy 
[155]. These publications, however, did not correlate the skin surface distribution to the 
absorption of the model drug into the skin.  
To address this topic concerning the effect of inhomogeneous donor formulation 
distribution on in vitro permeation results, in vitro finite dose permeation experiments were 
performed applying a donor by two different methods, i) distribution with a punch, and ii) 
distribution with a disc. To distinguish between skin with and without contact to the donor 
formulation, aqueous drug solutions were stained with a dye. The drugs employed in this 
study were caffeine and flufenamic acid (FFA). After incubation, the application area was 
determined by a newly developed computer-based method to ensure objectivity and to 
handle high-throughput data processing.  
The influence of the application area on the permeation was investigated with respect to its 
impact on the variability of the data.  
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Furthermore, lateral drug distribution was analyzed by quantification of skin biopsies with 
and without contact to the donor formulation.  
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4.3 Methods 
4.3.1 Materials and instruments 
All materials used were of highest analytical grade and were used as purchased.  
Ringer’s solution was provided by Fresenius Kabi, Bad Homburg, Germany. Purified water 
was prepared by a Millipore Synthesis device (Millipore GmbH, Schwalbach, Germany).  
The following instruments were used: static Franz diffusion cells type 4G-01-00-20 
(PermeGear, Riegelsville, PA, USA), incubation area 1.767 cm² and acceptor volume 12.1 ml, 
dialysis membranes with MW-cut-off of 12-14 kDa (Medicell International Ltd, London, Great 
Britain), 25 mm syringe filters 0.2 µm cellulose acetate membrane (VWR International, West 
Chester, PA, USA).  
4.3.2 Skin 
Human abdominal skin was obtained from female Caucasian donors undergoing plastic 
reduction surgery at the Department of Plastic and Hand surgery, Caritaskrankenhaus, 
Lebach, Germany. The skin was prepared according to [32] and stored in the freezer at -26°C 
for a maximum of six months. During this time the skin’s absorption properties are not 
changed [38-40]. For this study, skin of three donors was used. The study was approved by 
the Ethical Committee of the Aerztekammer des Saarlandes no. 204/08. 
Heat-separated epidermis (HSE) was prepared according to [45].  
4.3.3 Permeation experiments 
Permeation experiments were performed in a static Franz diffusion cell as described 
elsewhere [43]. Before incubation, the epidermis was equilibrated with the acceptor 
solution for one hour resulting in complete hydration. The acceptor solution consisted of PBS 
pH 7.4 for caffeine and Soerensen phosphate buffer pH 7.4 for flufenamic acid (FFA). To 
prevent microbial contamination the acceptor was stabilized with 0.05% (w/v) sodium azide.  
Caffeine was used in a concentration of 1mg/ml in PBS without NaCl and stained with 0.1% 
(w/v) methylene blue (sodium chloride was omitted due to salt formation with methylene 
blue). Previous studies have shown that the same permeation coefficients are obtained with 
and without NaCl.  
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FFA was used in a concentration of 1 mg/ml in Soerensen phosphate buffer stained with 
0.1% (w/v) eosin Y. 
All permeation experiments were performed with the donor chamber sealed by parafilm and 
aluminium foil to avoid crystallization due to solvent evaporation.  
Samples were taken from 0 h to 41 h. For each set of experiments 6 to 8 single experiments 
were carried out. The removed acceptor solution (400 µl) was replaced immediately by fresh 
buffer. The drug concentration in the acceptor never exceeded 10% of the solubility of the 
drugs in the respective receptor solution. 
4.3.4 Application of the donor 
Different finite dose application schemes were applied:  
• Punch: application of 17.6 µl of the donor formulation, then distribution of the 
formulation by 360° rotation of a Teflon punch (in-house, 14 mm diameter), removal 
of the punch and covering with a Teflon disc with a diameter of 14 mm. The drug 
amount removed with the punch was later determined by extraction.  
• Disc: application of 15.6 µl of the donor formulation, then distribution and covering 
with a Teflon disc with a diameter of 14 mm according to [50].  
In all finite dose experiments, a dose less than 10 µl/cm² was incubated with the skin to 
meet finite dose conditions.  
4.3.5 Mass recovery 
After incubation, all compartments were thoroughly examined for drug content: the 
remaining donor on the surface of the skin, drug on the parts of the Franz diffusion cell, and 
the skin. Caffeine was extracted from the skin with methanol 50% (v/v), sonication for 
30 min and further shaking for one hour followed by filtration through a cellulose acetate 
filter. FFA was extracted with 0.05 N NaOH for two hours at room temperature and filtration 
through cotton.  
In all experiments, a total mass recovery of 92.4 to 99.7% for caffeine and 94.0 to 114.5% for 
FFA were found. 
The extraction power of the drug from HSE was determined with standard solutions being  
97.8 ± 3.8% for FFA [32] and 87.4 ± 5.1% for caffeine [18].  
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4.3.6 Drug quantification 
Caffeine and FFA were quantified according to [18]. For calibration, both substances were 
dissolved in the respective extraction medium in concentrations of 0.03 – 20 µg/ml. 
Stability tests were performed for both substances in all solvents used for at least 41 h at 
32°C to ensure no degradation would take place during incubation. The dyes had no 
influence on the analytics and the permeation of the drugs.  
4.3.7 Analysis of the application area 
For accurate determination of the application area, the donor formulation was stained with 
a dye. After incubation, the dye was still visible on the skin surface and the contact area of 
the donor formulation with the skin could be analyzed.  
Following incubation, the skin was removed from the Franz diffusion cell and the donor 
distribution over the skin surface was visualized by means of a scanner with a resolution of 
1200 dpi as .tif data. The scans were analyzed by a two-step approach to check for 
formulation coverage and homogeneity of distribution.  
The application area of each experiment was calculated individually. First, the coverage was 
determined by using a hue-saturation-value (HSV) colour model [156] and by comparison to 
a non-stained skin sample. Second, the stained area was inspected for homogeneity by 
comparison to a perfectly stained skin sample from infinite dose experiments using a red-
green-blue (RGB) colour model.  
To obtain the fraction of formulation coverage Φ (Eq. 4-1) each image file was mapped to 
HSV colour space using appropriate thresholds in the hue channel to separate stained and 
non-stained pixels (fig. 4-1 B, D). 
  
(Equation 4-1) 
To analyze the homogeneity of dye distribution the stained area of the sample skin after 
incubation (fig. 4-1 A, C) was compared to a reference image from infinite dose application 
with perfect staining (fig. 4-1 E, F). 
To measure the difference to perfect staining the images were mapped to RGB colour space 
and the absolute robust z-score (z-score) of intensities of a dye-dependent colour channel of 
a reference staining (infinite dose case) and the stained parts of finite dose sample image, 
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previously identified by the HSV method, was calculated according to:   
        (Equation 4-2) 
Here, x is the median of intensities in the separation channel of the sample image, ref is the 
median of intensities in the separation channel of the infinite dose reference image and σref 
is the median absolute deviation of the intensities in the separation channel of the infinite 
dose reference image. 
For methylene blue stained skin the red channel showed a Gaussian like distribution in 
intensities and allowed a clear separation (peak shift) between stained and unstained areas. 
For eosin Y stained skin the green channel showed the best separation potential.  
All methods were implemented using MATLAB 7.8.0 (The MathWorks, Natick, 
Massachusetts, USA) with the Image Processing Toolbox.  
Coverage, expressed as percentage of the whole incubation area and the homogeneity of 
distribution (z-score) were determined for each experiment and the mean of all experiments 
was calculated. 
 
 
Figure 4-1 Visualization of the application area from scans. A: caffeine stained with methylene blue, 
finite dose; B: caffeine stained with methylene blue, finite dose, coverage; C: FFA stained with 
eosin Y, finite dose; D: FFA stained with eosin Y, finite dose, coverage; E: caffeine stained with 
methylene blue, infinite dose (reference); F: FFA stained with eosin Y, infinite dose 
(reference); G: incubated with unstained drug solution (blank), identical for both drugs. 
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4.3.8 Lateral drug distribution 
Drug distribution in stained and unstained skin parts was analyzed after incubation in the 
permeation setup. 15.6 µl of the stained drug formulation were applied to the skin as a drop 
without further distribution. This setup led to inhomogeneous formulation distribution over 
the incubation area. Thus, not all skin available for diffusion was in contact with the donor 
formulation. After predetermined time intervals of incubation (after 41 h, and additionally 
for FFA after 2 h and 20 h), 5 mm biopsies were taken from both completely stained and 
from completely unstained skin parts of the skin inside the donor area of the Franz diffusion 
cell and analyzed for their drug content. This allowed for comparison of the biopsy with 
contact to the donor formulation to the one without contact.  
4.3.9 Statistics 
Statistical tests (student’s t-test) were performed with Sigma Stat 3 (SYSTAT Software Inc., 
Point Richmond, CA, USA) to determine significant differences in results. A significant 
difference was detected at p < 0.05.  
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4.4 Results 
4.4.1 Permeation profiles, uncorrected surface distribution  
The permeation profiles of caffeine were only slightly in accordance with typical finite dose 
profiles including an approach of the curve to a maximum (fig. 4-2, black circles). A flattening 
of the curve can only be assumed. For the disc application the profile is similar to infinite 
dose behaviour (fig. 4-2 B, black circles).  
In both application schemes, a similar cumulative drug amount permeated after 41 h 
incubation (punch: 38.4 ± 9.4 %/cm², disc: 37.7 ± 10.5 %/cm²) and a high variability between 
the single experiments was found (fig. 4-2).  
The permeation profiles of FFA resembled typical finite dose permeation graphs (fig. 4-3, 
black circles) approaching a maximum after longer incubation times. Both application 
methods led to this characteristic permeation profile. With the punch, however, the 
maximum was statistically lower than for the disc (fig. 4-3 B), i.e. 40.5 ± 2.6 %/cm² versus 
48.2 ± 3.4 %/cm² after 41 h incubation. The variability between the individual experiments 
was low.  
4.4.2 Donor surface distribution 
Coverage was similar for both dyes with high variability for all experiments (table 4-1). 
Results of this identification method for methylene blue are shown in fig. 4-1 B (compared to 
fig. 4-1 A), and for eosin Y in fig. 4-1 D (compared to fig. 4-1 C). 
Z-scores were dependent on the dye; however, within each group very similar (table 4-1). 
 
Table 4-1 Coverage and z-score of FFA and caffeine using different application methods. Mean ± SD.  
 FFA Disc FFA Punch Caffeine Disc Caffeine Punch 
Employed dye Eosin Y Eosin Y Methylene blue Methylene blue 
Coverage [%] 
67.9 ± 18.6 68.5 ± 16.2 74.2 ± 18.5 73.7 ± 18.1 
z-score 
0.7 ± 0.5 0.9 ± 0.7 4.9 ± 1.7 5.9 ± 0.4 
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Figure 4-2 Permeation profiles of caffeine through heat-separated epidermis. Black circles: Relative 
cumulative caffeine amount per applied dose normalized to total incubation area 
(uncorrected). Red triangles: Relative cumulative caffeine amount per applied dose 
normalized to application area (inclusion of application area). Donor: caffeine 1 mg/ml. A: 
punch application, n=7. B: disc application, n=6. Mean, SD (provided only in one direction for 
the sake of clarity).  
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Figure 4-3 Permeation profiles of FFA through heat-separated epidermis. Black circles: Relative 
cumulative FFA amount per applied dose normalized to total incubation area (uncorrected). 
Red triangles: Relative cumulative caffeine amount per applied dose normalized to application 
area (inclusion of application area). Donor: FFA 1 mg/ml. A: punch application, n=8. B: disc 
application, n=8. Mean, SD (provided only in one direction for the sake of clarity).  
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4.4.3 Permeation data combined with calculated application area/coverage 
To find out whether the application area had an effect on permeation, the previously 
obtained permeation profiles for caffeine and FFA were normalized to the application area 
of each single experiment.  
Inclusion of the application area led to a decrease in variability of the permeation profiles of 
caffeine (fig. 4-2, red triangles). The relative standard deviation decreased strongly, too, and 
was slightly reduced over the incubation time (e.g. after 41 h for the punch 24% before and 
11% after correction).  
The permeation experiments with FFA exhibited a much lower variability between the 
different experiments compared to caffeine, even though the coverage was similar to the 
caffeine experiments. After including the application area, the variability between the 
experiments (fig. 4-3, red triangles), as well as the relative standard deviation (e.g. after 41 h 
for the punch 7% before and 25% after correction) increased highly. 
4.4.4 Lateral drug distribution 
After 2 h incubation with FFA, only in the skin parts in contact with the donor formulation 
FFA could be detected (fig. 4-4). With increasing incubation time, the FFA amount in the 
stained skin parts decreased while in the non-stained parts it increased. After 20 h no 
significant difference between stained and non-stained skin could be detected any more 
(2.33 ± 2.52% of applied dose vs. 0.31 ± 0.05% of applied dose, mean ± SD), and after 41 h 
the amount of FFA in biopsies with or without staining was similar (0.28 ± 0.04% of applied 
dose vs. 0.26 ± 0.01% of applied dose, mean ± SD).   
For caffeine, no lateral distribution could be observed after 41 h incubation. 
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Figure 4-4 Relative drug amount determined in 5 mm diameter skin biopsies of stained or non-stained 
skin parts after incubation in FD-C. Donor application as drop: A: Caffeine after 41 h 
incubation, n=7. B: FFA after 2 h, 20 h, 41 h incubation, n=3. T-test: *: p<0.01. Mean ± SD. 
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4.5 Discussion 
The goal of this study was to evaluate the influence of drug distribution of the application 
area on the results of finite dose permeation experiments using aqueous donor solutions. 
Therefore, two different application methods were tested and an automated detection 
system for surface distribution based on dyes was developed.  
4.5.1 Dye as a marker for skin contact with the donor formulation 
The aqueous donor phase employed in this study shows a high contact angle on the skin 
surface and therefore does not spread easily. The highly water soluble dyes employed in this 
study can be assumed to remain in the aqueous donor solution and are not distributed 
laterally over the lipophilic stratum corneum, making them an ideal compound for marking 
the contact area of the hydrophilic formulation with the skin (application area).  
4.5.2 Suitability of the automated computer-assisted approach for determination of 
coverage 
Based on the analysis of hue values and z-scores by an automated computer-assisted 
method the determination of coverage and homogeneity is an objective method to 
characterize the formulation distribution on skin’s surface. However, since the HSV colour 
space is a cylindrical-coordinate representation, two thresholds to define the blank skin (hue 
range) have to be determined. Within this range all pixels from the sample skin image will 
count as blank skin and all pixels outside this range will count as stained skin. Hue values 
between 0.02 and 0.35 were chosen empirically to identify non-stained skin pixels from a 
non-stained skin sample (fig. 4-1 G). These thresholds did guarantee a conservative 
prediction of staining since no false positive pixels were detected in a negative test set with 
only blank skin samples. Changing these parameters can significantly impact the definition of 
the coverage. Thus, for every batch of experiments a blank reference skin sample image 
(fig. 4-1 G) should be used to gather appropriate thresholds. The original sample images of 
skin (fig. 4-1 A, C) showed excellent consistency with the determined application areas 
(fig. 4-1 B, D).  
Calculation of the absolute robust z-score requires a median intensity level and the median 
absolute deviation of the RGB colour channel of a perfectly stained reference skin sample 
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image (fig. 4-1 E, F). Since eosin Y showed z-scores near zero, this indicates that the dye 
distribution was close to a perfect staining (table 4-1). For methylene blue, the values are 
reasonable.  
Besides increasing the speed of the evaluation process, the great benefits from using this 
automated approach is objectivity and stability of coverage, and colour distribution analysis 
for finite dose experiments that is not possible using a manual inspection method. In 
addition, the transfer of this method to evaluate formulation distribution in vivo is possible, 
if digital images made by photography were used instead of the scanned. 
4.5.3 Permeation profiles and lateral drug distribution 
The permeation profiles for caffeine do not resemble the typical finite dose characteristics 
(fig. 4-2). It is possible that after 41 h the effect of donor depletion is just not yet visible in 
the permeation profiles due to slower permeation of caffeine.  
The effect of the application area on the permeation profiles depends on the drug 
employed. For FFA, the variability between the experiments increased after including the 
application area, leading to the assumption that other additional effects may influence the 
drug absorption. These effects may be explained by lateral distribution of the lipophilic FFA 
(log D ~2.2 at pH 7.4, estimated). Skin biopsies taken after different incubation intervals 
from stained and unstained skin resulted in information about the time profile of lateral 
distribution of FFA, which was distributed homogenously over the whole incubation area 
after 41 h. As caffeine is a relatively hydrophilic compound (log Ko/w -0.08) [18,50] it cannot 
be transported into the lipid bilayers as easily as FFA.  
Lateral distribution was investigated from aqueous solution. This medium was chosen to 
gain general data for a substance and make the data comparable to the extended Flynn 
database [157,158]. Moreover, penetration enhancing effects, e.g. of oils or ethanol, or even 
plasma [159], were excluded. In addition, using excised human skin in aqueous surrounding 
led to exclusion of the follicular route due to closure of the follicles during hydration [160]. 
A direct visualization of lateral drug distribution over time would be preferred. For 
fluorescent dyes, the fluorescent recovery after photo bleaching (FRAP) technique can be 
employed [117] to analyze lateral diffusion. However, quantitative results are difficult to 
obtain for non-fluorescent drugs due to the low amount of drug actually diffusing laterally 
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and thus of analytics. This problem is even increased by finite dose application. Thus, lateral 
distribution in our study was investigated by means of skin biopsies.  
4.5.4 Clinical relevance 
In vivo experiments are quite expensive and their number will be reduced in the future. 
Therefore, in vitro skin absorption studies are important to gain first information about the 
absorption kinetics of a substance. Correlations between in vitro and in vivo experiments 
have been shown previously [32-34,36]. Thus, for example for bioequivalence studies in vitro 
experiments are beneficial to determine e.g. the difference between two vehicles [82].  
Finite dose experiments are even closer to the real-life scenario of a patient applying a small 
amount of a topical formulation. Due to that similarity, finite dose experiments are of major 
interest to predict the drug absorption. During in vivo application, differences in the 
homogeneity of donor formulation distribution are also possible, thus an analysis of the 
influence of inhomogeneous donor distribution is important, too.  
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4.6 Conclusion 
As shown in this paper, including the application area does not automatically improve the 
results from skin permeation studies using aqueous solutions, leading to more consistent 
results. Depending on the physicochemical characteristics of the drug, the substance 
behaves differently. For the more hydrophilic substances (e.g. caffeine) the degree of 
contact to the skin is crucial for permeation and this parameter should be included in the 
analysis of finite dose experiments. For lipophilic substances, e.g. FFA, however, the 
application area has less effect on the permeation of the drug.  
It can be assumed that the lipophilicity of the drug plays a role on the degree of distribution 
over the lipophilic stratum corneum. One question that remains is whether a limit of 
lipophilicity exists up to where distribution has an influence on permeation. To answer this 
question, another study with substances covering a wide range of lipophilicity would be 
required.  
 
 
 5 Finite dose skin absorption – Comparison between simulation, 
pharmacokinetic modelling, and experiment  
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5.1 Abstract 
Skin absorption experiments are of great interest for determining the absorption of a 
compound to the skin. The mass profiles in each compartment give detailed information 
about the actual distribution of the drug in each compartment. As finite dose experiments 
are closer to the in vivo situation, they are of special interest.  
In this thesis, finite dose has already been applied to permeation experiments with heat-
separated epidermis. In the following chapter, the focus is on finite dose skin absorption 
experiments with full-thickness skin to obtain mass profiles in the different compartments. 
The experiments performed in this chapter include the finite dose application and analysis 
method previously established in the permeation experiments. The experimental mass 
profiles were investigated with respect to experimental data, pharmacokinetic modelling, 
and with a 2D diffusion model.  
The pharmacokinetic model developed in this study included the lateral skin part 
compressed in the Franz diffusion cell during incubation and could fit the experimental 
profiles correctly, also in the lateral compartment.  
Furthermore, the diffusion model adapted to finite dose reasonably predicted the mass 
profiles in the different compartments.  
  5 Finite dose mass profiles 
 87 
5.2 Introduction 
As transdermal delivery of drug through the skin is gaining more relevance nowadays, the 
pharmaceutical industry is interested in evaluating the absorption of chemicals to the skin. 
Besides, the cosmetic industry is also interested in evaluating the systemic availability of 
cosmetically used substances, which normally should be avoided. To achieve this, usually 
infinite dose skin absorption experiments are performed. However, these experiments 
mainly give information about the steady-state conditions, but are not suitable for obtaining 
detailed information about the actual absorption process in the transient state. For the 
latter situation finite dose experiments are better suited.  
As defined in the OECD guideline 428 [27] and the guidance document 28 [28], finite dose 
experiments are characterized by an application volume of 10 µl/cm² or less to the skin. This 
donor volume is much closer to the dermal application situation in vivo, where usually only a 
small amount of a topical formulation is evenly distributed on the skin surface. Finite dose 
experiments allow for estimation of the absorption of chemicals from a patient situation, a 
working environment, or a cosmetic application.  
Most studies investigate the permeation of a drug through a membrane, and do not focus on 
the drug amount in the skin. To obtain a higher resolution of the drug in the different skin 
layers, penetration experiments are performed, separating the skin into different surface 
parallel sections. Thus, the concentration of the drug in the different skin layers can be 
determined. From this analysis, information about the absorption behaviour of the 
substance to the skin can be gained, e.g. the formation of a drug depot in the upper skin 
layers [8,9].  
However, as skin absorption experiments are generally time consuming, mathematical 
descriptions are useful tools to investigate the absorption behaviour and to reduce the 
number of experiments. Mathematical predictions of substance absorption can significantly 
reduce the number of experiments. Different models are available, most of them however 
solely regard the permeation profiles of a drug through a skin membrane [101,128] and not 
the drug amount in each skin layer.  
To account for finite dose application and the analysis of the drug amount in each skin layer, 
in this study finite dose skin penetration experiments were performed and the drug amount 
in each skin layer was determined.  
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As mathematical descriptions are not applicable without proper differentiation between the 
compartments, in this study the different compartments were carefully evaluated. In our 
study, a highly standardized method for tape-stripping the SC was employed, which required 
stretching of the skin before tape-stripping. To correct the experimental data for this setup, 
a stretching factor was necessary. When applying another tape-stripping technique, this 
correction may not be required. For example Lademann et al. [135] applied a roller to apply 
the pressure, which ensures that the complete surface of the SC can be stripped in vivo. Due 
to this setup, stretching of the skin is not necessary.  
Furthermore, a pharmacokinetic model was developed to describe the mass profiles of the 
drug in each compartment in this setup. The novelty of this model was the separation of the 
skin into not only the stratum corneum (SC) and the deeper skin layers (DSL), but also into an 
additional lateral skin part. This compartment is usually completely neglected during 
mathematical descriptions of experimental data.  
To simulate the mass profiles in the different compartments, a detailed diffusion model 
previously developed for infinite dose [19] was adapted to the finite dose scenario. The 
input parameters for this model were previously derived from infinite dose experiments 
[18], and the same parameters were used for the finite dose case. It has been shown 
previously that parameters derived from infinite dose can be employed to predict finite dose 
kinetics [128], whereas estimation from finite dose experiments may show great 
intraindividual variability [161].   
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5.3 Materials and methods 
5.3.1  Materials and instruments 
The following chemicals were used: potassium dihydrogen phosphate, citric acid x H2O 
(Merck, Darmstadt, Germany), caffeine, flufenamic acid, acetonitrile, methanol (Sigma-
Aldrich, Steinheim, Germany), orthophosphoric acid, sodium hydrogen phosphate dihydrate 
(Riedel-de Haën, Sigma-Aldrich, Seelze, Germany). Purified water was prepared by a 
Millipore Synthesis device (Millipore GmbH, Schwalbach, Germany).  
Static Franz diffusion cells type 6G-01-00-15-12 with a acceptor volume of 12.1 ml and an 
incubation area of 1.767 cm² were provided by Perme Gear, Riegelsville, PA, USA; tesa® Film 
kristall-klar, (t-tape, 33 m x 19 mm, #57330-00000-02, cut to pieces of 16 x 19 mm) was 
provided by tesa AG, Hamburg, Germany; cryomicrotome (MEV) was provided by SLEE, 
Mainz, Germany; centrifuge (Rotina 420R) was provided by Hettich Zentrifugen, Tuttlingen, 
Germany. 
5.3.2 Skin 
Excised human full-thickness skin was obtained from three female Caucasian donors 
undergoing abdominal plastic surgery at the Department of Plastic and Hand surgery, 
Caritaskrankenhaus, Lebach, Germany. The study was approved by the Ethical Committee of 
the Aerztekammer des Saarlandes no. 204/08.  
The skin was treated according to [32] and stored in the freezer at -26°C for a maximum of 
six months. When taking a skin punch on the day of the experiment, care was taken to 
strictly avoid repeated freezing and thawing of the skin. It has been shown that this 
treatment does not impair the barrier function of the skin [38-41].  
5.3.3 Skin absorption experiments 
To conduct a skin absorption experiment, a 25 mm punch of the frozen skin was taken on 
the day of the experiment and allowed to thaw. After cleaning the skin with distilled water 
and drying it with cotton balls, the skin was mounted in a Franz diffusion cell with the 
epidermis side up. The acceptor compartment was filled with Soerensen phosphate buffer 
pH 7.4, and the skin was equilibrated for one hour with the acceptor solution with a sealed 
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donor chamber (with parafilm and aluminium foil) to avoid water evaporation. Preliminary 
experiments showed that longer equilibration time did not change the results.  
The donor consisted of the respective drug dissolved in Soerensen phosphate buffer pH 7.4 
in concentrations of 1 mg/ml for flufenamic acid (FFA), and 1 mg/ml and 12.5 mg/ml for 
caffeine.  
25 µl of the donor solution was applied to the skin by means of a positive displacement 
pipette. The donor formulation was spread evenly over the incubation area by means of a 
teflon punch with a diameter of 14 mm, which was turned through 360°. After removal of 
the punch, a teflon disc with a diameter of 14 mm was placed onto the donor solution to 
enhance the contact to the skin surface during incubation. The actual amount of donor 
formulation remaining on the skin was later determined from the washing of the punch.  
In all experiments, a finite dose was achieved according to [27,28] (donor volume remaining 
on the skin surface less than 10 µl/cm²). After application of the donor solution, the donor 
compartment was sealed again with parafilm and aluminium foil. The whole setup was 
incubated at 32 ± 1 °C. 
5.3.4 Isolation of the different skin compartments  
After incubation, the skin was cleaned of remaining donor formulation by cotton balls. Then, 
tape-stripping was performed in vitro with tesa® Film kristall-klar under highly standardized 
conditions according to chapter 10 Appendix.  
After complete removal of the SC by tape-stripping, the rest of the skin was frozen using 
expanding carbon dioxide. Then, a punch of 13 mm diameter was taken from the stripped 
area of the frozen deeper skin layers (DSL) and cut by cryo-sectioning.  
The lateral skin parts were leftover and were treated as explained in chapter 5.3.5.  
5.3.5 Determination of the stretching factor for data correction 
The experimental methodology (skin stretching before tape-stripping and the usage of a 
smaller punch to separate the DSL) does promote the formation of a »pseudo-lateral« skin 
part in addition to an actual lateral skin part (fig. 5-1). Since this effect does falsify mass 
recovery results and the degree of stretching of the skin is typically unknown, the stretching 
factor f (Eq. 5-1) was introduced to scale mass recovery data from the experiment. 
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We assumed a horizontal uniform drug distribution within each model compartment (Donor, 
SC, DSL, Lateral, and Acceptor) and used a first order mass balance model to estimate the 
stretching factor f.  
Incubated
IncubatedStretched
A
AAf −=       (Equation 5-1) 
f is the ratio of the difference between stretched area AStretched and incubated area AIncubated 
normalized to AIncubated. We assumed an artificial flux from the donor compartment directly 
to the lateral compartment via the »pseudo-lateral« compartment that corresponds to skin 
stretching induced by the used tape-stripping procedure (fig. 5-1 B). In this mass balance 
model the rate constants of the flux through the stretched skin part outside of the stripped 
area to the lateral skin part should commensurate with the rate constants to the skin parts 
of the incubated area. The proportionality factor should correspond to the scaling factor f. 
The set of ordinary differential equations (ODEs) of the model was solved numerically and 
the rate equations as well as the stretching factor f were fitted to the mass over time curves 
by minimizing the root mean square deviation (RMSD) of the fitted results and experimental 
data points. The procedure was implemented using Python 2.7.1 and the SciPy package 
[162].  
The amount of drug in the SC, DSL and the lateral skin part was scaled according to the ratio 
of surface area of the stretched skin and the area of incubation. 
 
 
Figure 5-1 Schematic visualization of the geometric problems associated with stretching the skin before 
tape-stripping. A: skin during incubation. B: skin stretched before tape-stripping.  
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5.3.6 Validation of the stretching factor 
To validate the stretching factor, full-thickness skin was incubated in a Franz diffusion cell 
with the donor formulation. After incubation, the skin was not stretched in preparation for 
tape-stripping. Instead, a 16 mm biopsy was taken to remove all incubated skin parts. The 
remaining skin rest was regarded as lateral skin parts without any contact to the donor 
formulation. All skin compartments (Donor, Incubated skin (SC+DSL), Lateral skin parts, 
Acceptor) were quantified for their drug content.  
For each drug the longest incubation time of the experimental range was chosen, for FFA 6 h 
and for caffeine 12 h. The same concentration of 1 mg/ml was applied for both drugs.  
5.3.7 Mass balance  
After incubation, the different compartments of the setup were thoroughly examined. The 
remaining donor on the surface of the skin, including remaining formulation on the upper 
part of the Franz diffusion cell was removed by means of cotton and extracted with the 
respective extraction fluid for two hours. The tape-strips (SC), the cryo-cuts (DSL), and the 
lateral skin parts were treated identically, with an additional centrifugation step for 10 min 
at 1000 rpm for the DSL extracts and removal of the supernatant for analysis. The samples 
from the acceptor were measured without further dilution steps.  
FFA was extracted using 0.05 N sodium hydroxide solution and caffeine with phosphate 
buffer pH 2.6 for 2 h. For all experiments, the obtained total recovery for FFA ranged from 
83.8% to 96.8% and for caffeine from 87.9% to 107.3%.  
5.3.8 Quantification 
Samples were analyzed by Reversed-phase high performance liquid chromatography (RP-
HPLC) using an isocratic Dionex HPLC system with a Lichrospher® 100/RP-18 column with a 
Lichrocart 4-4 Lichrospher® 100/RP-18 guard column (Merck-Hitachi, Darmstadt). Software: 
Chromeleon 6.60 SP1 Build 1449.   
For caffeine, the mobile phase was composed of phosphate buffer pH 2.6 (1.16 ml/l 
orthophosphoric acid, 2.04 g/l potassium dihydrogen phosphate): acetonitrile (90:10), (v/v). 
Injection volume: 50 µl; flow rate: 1.4 ml/min; retention time: 4.9 ± 0.2 min; detection 
wavelength: 262 nm; detection limit: 20 ng/ml; quantification limit: 30 ng/ml.   
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For FFA, the mobile phase was composed of methanol: buffer pH 2.2 (22.75 g/l citric acid 
monohydrate, 0.4 g/l Na2HPO4 x 2H2O) (80:20), (v/v). Injection volume: 50 µl; flow rate: 
1.2 ml/min; retention time: 3.3 ± 0.2 min; detection wavelength: 284 nm; detection limit: 
30 ng/ml; quantification limit: 50 ng/ml.  
The detection limit was determined as the threefold standard deviation of the y-axis 
intercept divided by the mean of the slope. The quantification limit was determined by the 
fivefold standard deviation of the y-axis intercept divided by the mean of the slope. 
For calibration, both substances were dissolved in the respective extraction medium in 
concentrations of 0.03 – 20 µg/ml. Stability tests in Soerensen buffer showed that both 
drugs were stable in this buffer up to 30 h incubation at 32°C. 
5.3.9 Pharmacokinetic modelling 
Pharmacokinetic (PK) modelling was applied to analyze mass profiles in the different 
compartments for FFA and caffeine finite dose experiments. The model treats the different 
skin layers as well stirred compartments. First-order kinetics was assumed to describe the 
substance mass flux for every compartment, which yielded a set of ODEs. An explicit lateral 
compartment was modeled as an extension of the classical models. The set of ODEs was 
numerically integrated and fitted (nonlinear least squares regression) to experimental data 
using the Python programming language with the SciPy package (scientific python). The root 
mean square deviation (RMSD) was used as an indicator for accuracy. A grid search was 
applied to find appropriate starting values in order to avoid sticking in a local minimum. 
In the PK model a lateral compartment was added, into which the drug can enter through 
the SC or the DSL compartment (fig. 5-2). In this model the transport constants k5 and k6 
display an averaged transport via the SC and DSL to the lateral compartment. 
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Figure 5-2 Pharmacokinetic model developed to analyze the drug distribution between various relevant 
compartments in the setup.  
 
5.3.10 Detailed diffusion model 
The transport is modeled by a diffusion process in an idealized, two-dimensional model 
membrane. The model has been described previously for an infinite dose setting [18,19]. The 
core part of the model is a brick-and-mortar like structure, which represents the SC. On top 
and bottom side of this structure two additional compartments were added. These model 
the donor chamber (don) of the diffusion cell and the DSL, respectively. The heights for 
donor and DSL compartments are hdon=0.1 mm and hDSL=3 mm, respectively. Initially, no 
substance is present in SC and DSL, and a defined concentration matching the experimental 
setup is provided in the donor. A lateral compartment was not included in the model. A 
schematic graph of the diffusion model can be found in chapter 1 Introduction fig. 1-9.  
The model relies on a variety of diffusion and partition coefficients, which are provided in 
table 5-1. All parameters employed in this model were taken from infinite dose experiments 
performed previously [18], except Ddon, which has been calculated for the finite dose 
scenario. A relationship to predict the diffusion coefficient Da in an aqueous solution from 
the solute molecular weight was proposed by Anderson et al. [163] with 
  naa MWDD −⋅= 0         (Equation 5-2) 
where Da is the diffusion coefficient in a certain medium, n and 
0
aD  are constants associated 
with the medium at a defined temperature, and MW the molecular weight in Da. Using 37 
substances and their corresponding molecular weight and diffusion coefficient in water at a 
given temperature [164] the previous equation was fitted using a linear model. 
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Table 5-1 Input parameters for simulation of skin absorption with 2D diffusion model from [18,19] and  
the calculated values for Ddon. 
Parameter  FFA Caffeine 
Ddon [µm
2
/s] 686.33 809.92 
Dlip [µm
2
/s] 3.055 5.833 
Dcor [µm
2
/s] 0.014166 0.003888 
DDSL [µm
2
/s] 136.11 63.89 
Klip/don  20.32 2.15 
Kcor/lip  0.21 2.22 
KDSL/lip  0.1 0.08 
 
5.3.11 Statistics 
Graph Pad Prism was used for calculating student t-test. Significant differences were found 
at p<0.05.  
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5.4 Results 
5.4.1 Validation of the stretching factor 
By scaling of the experimental data the drug amount in the lateral skin parts decreased and 
in the SC+DSL compartments it increased. Experiments with unstretched skin resulted in 
similar drug amounts in the SC+DSL and in the lateral skin compartments as the scaled 
experimental data set (fig. 5-3). No significant differences could be found between the 
scaled experimental data and the data obtained from the experiments with unstretched skin 
(Reference) both for FFA and caffeine. The difference between Reference and Original in the 
lateral part was significant for both drugs.   
 
 
Figure 5-3 Relative drug amount recovered from the different compartments. Donor: Formulation 
recovered from the skin surface and surface of donor compartment. SC+DSL: incubated skin 
parts. Lateral: Skin outside of the incubated area. Acceptor: drug in acceptor compartment. 
Original: data from tape-stripping experiments. Scaled: data from tape-stripping experiments 
scaled with stretching factor. Reference: data from experiments without stretching. A: FFA: 
n=5. B: caffeine: n=4. 
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5.4.2 FFA mass profiles 
- Experimental data 
FFA finite dose experiments resulted in a relatively fast decrease of drug in the donor. 
Already after 15 min the drug amount in the donor was reduced to around 60% of the 
applied dose (fig. 5-4 A). After this quick donor reduction, the donor continued to deplete 
more slowly, reaching around 20% remaining in the donor compartment after 6 h 
incubation. In the SC around 30% of the applied dose was found after 15 min and a plateau 
was reached and maintained until 2 h after application (fig. 5-4 B). Afterwards, the FFA 
amount decreased to 10-20% with high variability at the 4 h and 6 h data points. The drug 
amount in the DSL increased constantly, reaching a plateau at approximately 50% after 4 h 
of incubation (fig. 5-4 C). No FFA could be quantified in the acceptor compartment until 6 h 
of incubation due to analytical reasons (fig. 5-4 D). The drug amount determined in the 
lateral skin part appeared to increase after longer incubation (fig. 5-4 E). However, data is 
affected by high variability, especially for later time points, a tendency comparable to the 
other compartments.  
 
- Pharmacokinetic model 
The donor could be correctly fitted by the PK model, decreasing rapidly in the first hour to 
around 50%, and then decreasing slowly to around 20% after 6 h (fig. 5-4 A). The SC profile 
could also be correctly fitted; however the drug amount in the SC for the 30 min and 60 in 
time points was slightly over predicted, but clearly in the range of the standard deviation 
(fig. 5-4 B). The DSL was correctly fitted by the PK model, too (fig. 5-4 C). Since no FFA was 
obtained in the acceptor compartment (fig. 5-4 D), it was obviously not possible to fit the 
efflux rate constant k7. In the lateral compartment, the profile was fitted reasonably with the 
PK model (fig. 5-4 E). Values for rate constants of the PK model are provided in table 5-2.  
 
- Detailed diffusion model 
The donor decreased more slowly than in the experiment and the PK model over the whole 
experimental period (fig. 5-4 A). Values range from slightly less than 80% after 15 minutes to 
roughly 30% after 6 h, and the deviation after 4 h and 6 h is well within the range of the 
standard deviations. In the SC, the consistency between experiment and simulation was 
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reasonable (fig. 5-4 B). After an initial phase with no substance present until 30 minutes, the 
amount in the DSL increased to reach a maximum at 50%, corresponding to the 
experimental data (fig. 5-4 C). The plot shows an inflection point at roughly 2 h indicating the 
finite dose character of the experiment. In the acceptor low FFA amount (less than 3%) was 
simulated after 6 h (fig. 5-4 D).  
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A B  
C D  
E  
Figure 5-4 FFA mass profiles over time: experimental data, PK fitting, and detailed diffusion simulation. 
A: Mass profile of the Donor compartment. B: Mass profile of the SC compartment. C: Mass 
profile of the DSL compartment. D: Mass profile of the Acceptor compartment (diffusion 
model with mass leaving the system). E: Mass profile of the Lateral compartment (diffusion 
model data not available). 
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5.4.3 Caffeine mass profiles 
- Experimental data 
In the 1 mg/ml caffeine experiments, the drug in the donor did not decrease as fast as for 
FFA. After 5 min, still more than 85% of the initial dose could be found, decreasing slowly 
and reaching around 60% remaining on the skin after 6 h (fig. 5-5 A). At the last measuring 
time point after 12 h, still more than 40% of the drug was found in the donor. In the SC, a 
plateau at around 25% was reached after 2 h and maintained until 6 h, then slowly 
increasing to around 35% at the end of incubation after 12 h (fig. 5-5 B). The amount of drug 
in the DSL remained very low until 6 h due to values close to the LLOQ, and then increased to 
around 10% after 12 h (fig. 5-5 C). Only after the longest incubation at 12 h, caffeine was 
found in the acceptor (fig. 5-5 D). However, the variation was quite high due to 
concentration values close to the LLOQ. The caffeine amount in the lateral compartment 
slowly increased, reaching around 10% of the applied dose after 12 h incubation (fig. 5-5 E).  
For the 12.5 mg/ml experiments, the course of relative drug amount in the donor was 
similar to the 1 mg/ml data (fig. 5-6 A). In the SC, a plateau was immediately reached 
between 10% and 15% and maintained until 6 h after application (fig. 5-6 B). The amount of 
caffeine in the DSL increased slowly, reaching around 10% after 6 h (fig. 5-6 C). After 6 h 
incubation, around 5% of the applied caffeine was found in the acceptor phase (fig. 5-6 D). 
No caffeine was found at earlier time points. In the lateral compartment the caffeine 
amount increased to around 15% after 6 h (fig. 5-6 E).  
 
- Pharmacokinetic model 
The PK model showed a good agreement with the donor profile of caffeine 1 mg/ml (fig. 5-5 
A). Both SC and DSL profiles were reasonably fitted (fig. 5-5 B, C). The acceptor was also 
nicely fitted (fig. 5-5 D), as well as the lateral compartment (fig. 5-5 E).  
For the 12.5 mg/ml experiments the donor profile was excellently fitted by the PK model 
(fig. 5-6 A). The same was true for the SC compartment (fig. 5-6 B) and the DSL compartment 
(fig. 5-6 C). The acceptor was correctly fitted (fig. 5-6 D), as well as the lateral skin parts (fig. 
5-6 E).  
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- Detailed diffusion model 
As relative drug amounts in the diffusion model are independent of the concentration in the 
donor, fig. 5-5 and 5-6 show identical plots, with the exception of the longest incubation 
times (12 h for 1 mg/ml, 6 h for 12.5 mg/ml). The donor depletes more slowly than for FFA 
with values of 60% after 6 h and 40% after 12 h. The SC diagrams show a characteristic 
plateau slightly below 30% after 150 minutes. Mass transfer into the DSL increased to more 
than 20% after 12 h. About 5% of the drug left the membrane into the acceptor after 12 h.  
For 1 mg/ml, the experimental data is simulated well in the donor compartment, the SC, and 
the acceptor. However, the amount in the DSL is highly over predicted with the model for 
longer incubation times.  
For 12.5 mg/ml, the donor compartment and the DSL are well simulated. The caffeine 
amount in the SC is however over predicted, whereas in the acceptor it is under predicted.  
 
 
Table 5-2  Rate constants and standard errors (SE) of the pharmacokinetic model  
Parameter FFA  Caffeine1mg  Caffeine 12.5 mg  
 Mean [%/min] SE Mean [%/min] SE Mean [%/min] SE 
k1 3,70E-02 3,45E-03 3,81E-03 2,09E-04 5,92E-03 5,68E-04 
k2 4,52E-02 5,29E-03 5,73E-03 4,66E-04 2,11E-02 3,08E-03 
k3 6,78E-03 2,80E-04 2,76E-04 3,14E-04 4,35E-03 1,55E-03 
k4 2,29E-04 2,42E-04 1,52E-03 1,90E-03 2,38E-03 2,68E-03 
k5 1,00E-03 8,42E-04 1,96E-03 7,79E-04 4,52E-03 1,78E-03 
k6 7,12E-04 1,15E-04 1,50E-03 4,06E-04 5,53E-03 1,61E-03 
k7 - - 1,05E-03 4,30E-04 2,13E-03 4,37E-04 
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A B  
C D  
E  
Figure 5-5 Caffeine (1 mg/ml) mass profiles over time: experimental data, PK fitting, and detailed 
diffusion simulation. A: Mass profile of the Donor compartment. B: Mass profile of the SC 
compartment. C: Mass profile of the DSL compartment. D: Mass profile of the Acceptor 
compartment (diffusion model with mass leaving the system). E: Mass profile of the Lateral 
compartment (diffusion model data not available). 
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Figure 5-6 Caffeine (12.5 mg/ml) mass profiles over time: experimental data, PK fitting, and detailed 
diffusion simulation. A: Mass profile of the Donor compartment. B: Mass profile of the SC 
compartment. C: Mass profile of the DSL compartment. D: Mass profile of the Acceptor 
compartment (diffusion model with mass leaving the system). E: Mass profile of the Lateral 
compartment (diffusion model data not available).  
  5 Finite dose mass profiles 
 104
5.5 Discussion 
5.5.1 Experimental data 
Validation of the stretching factor showed that this method is a suitable method to correct 
the experimental data for the conditions during incubation and tape-stripping.  
The experimental mass profiles of caffeine in the SC are clearly different between the 
different concentrations. For caffeine 1 mg/ml around 25 to 35% of the drug can be found in 
the SC, whereas for the higher concentration the values reach only up to 15%. One 
explanation for the different profiles is a saturable effect in the SC, allowing only a certain 
caffeine amount to be taken up by the SC, e.g. reversible protein binding to keratin 
[95,165,166].  
5.5.2 Pharmacokinetic model 
The PK model is a model to completely describe finite dose absorption of the drugs 
employed in this study using a reasonable mass transport model. PK models using first-order 
rate constants were typically used as in vivo prediction tools [167,168] and a lot of effort was 
spent trying to relate rate constants to physicochemical properties of the diffusant and to fit 
a model to plasma-level curves or in vitro absorption [169,170]. Overview articles relating to 
one or two compartment PK models can be found in the literature [171-173].  
It has been shown that for in vitro skin absorption multi compartment modelling, a two 
compartment model is providing the best compromise of accuracy and complexity for a 
great variety of substances [78]. Thus, we developed a two compartment model and 
extended it to mass transport into the lateral part, which to the best of our knowledge has 
never been investigated before. However, the PK model is not able to predict mass profiles 
since it was not promising to relate rate constants to physicochemical properties of the 
diffusant and vehicle.  
To reduce the number of rate constants for the fitting procedure, an averaged transport 
(rate constants k5 and k6) between SC and Lateral compartment as well as between DSL and 
Lateral compartment, was assumed.  
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5.5.3 Detailed diffusion model 
The detailed diffusion model relies on input parameters, which are accessible in an 
experimental framework. In principle all parameters can be related directly to physico-
chemical properties of the substance. This is an advantage as the model has a predictive 
character. Although optimization of parameters is possible, it was not applied in this case. 
Since the presented model consists of 16 cell layers arranged in a fully aligned way, it is not 
possible to consider lateral diffusion in this case. 
Some differences between experiment and diffusion model were found, which can be easily 
explained by analytical reasons, e.g. concentration below the LLOQ in the acceptor for FFA.  
In general, the detailed diffusion model reasonably predicted the mass profiles in each 
compartment for both drugs over the experimental time of 6 h or 12 h. 
5.5.4 Comparison of the models 
The models employed in this study are very different and serve different purposes.  
The PK model is a compartmental model adapted to fit the entire experimental data, 
including the lateral compartment. In this approach the whole experimental setup and not 
just a small part of the experiment is modelled to gain insight into all effects occurring during 
incubation.  
The detailed diffusion model is a strongly divergent model, simulating the SC at a high 
resolution level of single corneocytes and the lipid phase. The major advantage of this model 
is the possibility of actually predicting finite dose mass profiles.  
5.5.5 Lateral skin parts 
Even after correction of the data, still a high amount of drug can be found in the lateral skin 
parts. Thus, it is essential to regard the lateral skin parts in the mass balance during finite 
dose skin absorption studies. Most studies investigating finite dose experiments do not 
discuss the lateral drug amount found in their studies. Lateral diffusion of benzyl alcohol into 
the clamped parts of the diffusion cell has been assumed previously [174].  
From microscopic pictures (fig. 5-7) taken both from untreated skin and from skin squeezed 
in a FD-C for 20 h, no significant difference was found for the SC thickness (p=0.218). The 
dermis, however, appeared much denser than before. The geometry of the skin is clearly 
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changed, reducing the possibility of using measured diffusivity and partition behaviour from 
fully hydrated skin experiments.  
 
 
 
 
Figure 5-7 Cross sections of skin biopsies from untreated skin (A), and from the lateral, compressed part 
of a skin sample squeezed in a Franz diffusion cell during incubation with buffer for 20 h (B). 
Stained with haematoxylin. Magnification 200 x.  
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5.6 Conclusion and outlook 
With the help of both mathematical models the experimental setup of finite dose skin 
absorption experiments in a Franz diffusion cell can be thoroughly investigated. The PK 
model is suitable for describing the whole setup and gives information about the diffusion 
process also into the lateral skin parts. This approach may expand the knowledge about the 
whole absorption process in a Franz diffusion cell.  
The detailed diffusion model on the other hand can predict the diffusion of FFA and caffeine 
into the different skin compartments in a finite dose setup. If this model can be applied to 
further substances, in the future only infinite dose preliminary experiments to determine the 
input parameters would be required to predict the finite dose profiles.  
In the future, a homogenized model will be applied to the same experimental data to 
simulate the mass profiles in the different compartments. In this model, the SC structure is 
homogenized and transport over a wider area compared to the detailed diffusion model can 
be simulated. Furthermore, a lateral compartment is added. Thus, simulation of the drug 
transport into the different compartments including the lateral part is possible with one 
model. 
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6 Finite dose skin penetration: Concentration depth profiles – 
Comparison between experiment and simulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of the thesis made the following contributions to this chapter: Performed and 
interpreted all experiments. Wrote the chapter.   
 
The Wittum group in Frankfurt made the following contributions to this chapter: Developed 
the detailed diffusion model and adapted it to finite dose, and performed the simulations.  
  6 Finite dose concentration depth profiles 
 110
6.1 Abstract 
This chapter focuses on finite dose skin penetration experiments with a detailed resolution 
of the drug concentration over depth in the SC and in the DSL and comparison of the 
experimental concentration depth profiles with simulations of a 2D diffusion model.  
The detailed diffusion model for the prediction of concentration depth profiles in the SC and 
the DSL had previously been developed for infinite dose and was now adapted to finite dose. 
The concentration depth profiles of the model drugs Flufenamic acid (FFA) and caffeine were 
obtained experimentally and were compared to the detailed diffusion model.  
The detailed diffusion model could predict the concentration depth profiles of FFA well, both 
in the SC and the DSL. The concentration depth profiles of caffeine on the other hand were 
not predicted quite as well as for FFA, but the order of magnitude between experiment and 
simulation was the same.  
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6.2 Introduction 
As already described before in chapter 1 Introduction, skin penetration experiments give 
more information about the actual distribution of the drug in the different skin layers after a 
certain incubation time. For instance, the systemic absorption of a compound can be 
estimated from the drug content recovered in the SC [9]. 
However, due to extensive laboratory work and mathematical challenges, only few 
publications regard the concentration depth profiles of a substance in the skin layers, e.g. in 
the SC. When it comes to finite dose experiments, the number decreases even more due to 
analytical challenges.  
In some publications concentration depth profiles were simulated, but no comparison 
between the obtained results to experimental data was done [112,121,175,176].  
Thus, in our study both experiment and simulation were investigated, and the results of the 
two methods were compared. Finite dose skin penetration experiments with the model 
drugs Flufenamic acid (FFA) and caffeine from aqueous solution pH 7.4 were performed and 
the obtained concentration depth profiles were compared to the simulated profiles.  
The diffusion model employed for simulation predicted the finite dose profiles with the input 
parameters derived from infinite dose experiments.  
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6.3 Materials and Methods 
6.3.1 Penetration experiments 
Penetration experiments were performed with full-thickness skin in a Franz diffusion cell as 
described in chapter 5.  
6.3.2 Tape-stripping procedure 
Tape-stripping and SC quantification on tape-strips were performed under highly 
standardized conditions according to chapter 10 Appendix with tesa® Film kristall-klar. The 
first two tapes were extracted individually, and then always two tapes were pooled 
together.  
6.3.3 Cryo-sectioning of the deeper skin layers 
After removal of the SC by tape-stripping, the rest of the skin was segmented according to 
[32]. In short, after freezing of the tape-stripped skin, 25 µm slices of the DSL were cut by a 
cryo-microtome. The cuts were collected in pre-weighed glass tubes and the thickness of the 
skin layers was determined by their mass.  
6.3.4 Mass balance  
Mass balance was ensured by extraction of the drug from all skin parts and all devices in 
contact with the drug. Flufenamic acid (FFA) was extracted using 0.05 N sodium hydroxide 
solution, and caffeine with phosphate buffer pH 2.6, both under shaking for two hours at 
room temperature. The deeper skin layer extracts were centrifuged for 10 min at 1000 rpm 
and the supernatant carefully removed for analysis. A total recovery of 83.8% to 96.8% for 
FFA and 87.9% to 107.3% for caffeine for the single experiments was obtained.  
6.3.5 Quantification by HPLC 
FFA and caffeine were quantified according to chapter 5. For calibration, both substances 
were dissolved in the respective extraction medium in concentrations of 0.03 – 20 µg/ml.  
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6.3.6 Concentration depth profiles 
Concentration depth profiles were calculated from the drug amount in the different skin 
pools, the thickness of each pool and the depth inside the skin according to chapter 10 
Appendix.  
6.3.7 Detailed diffusion model 
The detailed diffusion model adapted to the finite dose case of chapter 5 was used to predict 
the concentration depth profiles of both drugs in the SC and the DSL. The input parameters 
employed in the simulation are given in table 5-1.  
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6.4 Results 
6.4.1 FFA 
- Experiment 
The shape of the experimental concentration depth profiles appeared as a two-phase shape 
with a steep decrease in drug concentration in the outermost SC layers and then a slower 
decrease from around 0.1 relative depth (fig. 6-1). The concentration depth profiles of FFA in 
the SC at the different time points resembled each other.  
The amount of drug in the DSL increased with increasing incubation time, from around 
4 µg/cm³ after 15 minutes to around 50 to 100 µg/cm³ after 6 h in the uppermost part of the 
DSL (fig. 6-2). The profiles decreased quickly after the first DSL layers and then decreased 
more slowly.   
 
- Simulation 
In the SC the shape of the simulated concentration depth profiles resembled an exponential 
decay for the shortest incubation time, and at longer incubation times the concentration 
depth profiles became linear. The simulation predicted the SC concentration depth profiles 
well, especially at the shorter incubation points. Afterwards, the correlation was still 
reasonable with only the first tape-strips varying from the simulation.  
In the DSL, the simulation under predicted the experimental concentration depth profiles for 
the incubation times 15 min and 30 min (fig. 6-2). Afterwards, for the time points 60 min and 
4 h the concentration depth profiles were well predicted. The shape of the simulation curve 
was similar to the experimental data. However, for 4 h and 6 h incubation time the 
simulation predicted a linearly decreasing depth profile in contrast to experimental data.  
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Figure 6-1 FFA concentration depth profiles in SC for different incubation times. Crosses and the line as a 
guide to the eye represent the simulated depth profiles. The experimental data points are 
plotted according to the individual experiment: A: black circles, B: blue triangles down, C: red 
diamonds, D: grey triangles up. N=3 for experiments 15 min to 4 h. For 6 h: N=4.  
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Figure 6-2 FFA concentration depth profiles in DSL after different incubation times. Crosses and the line 
as a guide to the eye represent the simulated depth profiles. The experimental data points are 
plotted according to the individual experiment: A: black circles, B: blue triangles down, C: red 
diamonds, D: grey triangles up. N=3 for experiments 15 min to 4 h. For 6 h: N=4.  
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6.4.2 Caffeine 
- Experiment 
For 1 mg/ml the caffeine amount in the SC was low after the shortest incubation time of 
5 min compared to the other incubation times (fig. 6-3). Afterwards, the concentration 
increased slowly over the whole depth of the SC. The shape of the concentration depth 
profiles appeared more or less linear for all time points.  
The drug amount in the DSL was very low for the 1 mg/ml experiments, and scattered 
around the limit of quantification. Too few data points above the LLOQ were available to 
create concentration depth profiles. Thus, the results are not shown and no simulation was 
performed. 
When applied at the high concentration of 12.5 mg/ml, the caffeine concentration in the SC 
strongly increased, leading to a caffeine concentration of over 10000 µg/cm³ in the first SC 
layers for all time points (fig. 6-4). Interestingly, the concentration values were roughly a 
factor of 12.5 higher than the data of the lower concentration of 1 mg/ml. The concentration 
depth profiles at the earlier time points slowly decreased over depth. At the later time 
points at 2 h and 6 h, however, the caffeine concentration appeared to remain constant over 
the whole SC depth.   
After application of the 12.5 mg/ml donor, caffeine could also be found in the DSL (fig. 6-5). 
After 30min, only few data points could be generated experimentally, whereas after 2 h and 
6 h reasonable depth profiles could be plotted. The caffeine concentration increased from 
around 4 µg/cm³ after 30 minutes to around 100 µg/cm³ in the outer DSL layers after 6 h. 
The profiles slowly decreased over depth.  
 
- Simulation 
As the diffusion model is calculating relative concentrations only, the simulated profiles for 
the different caffeine concentrations are connected by a factor of 12.5.  
For the low caffeine concentration, the depth profile in the SC was reasonably predicted for 
all time points (fig. 6-3). The shape of the experimental curves was reasonably simulated, 
with an exponential decay curve at shorter incubation times and linear decrease at longer 
incubation times.  
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The simulation of the high caffeine concentration was modelled not quite as well (fig. 6-4). 
After 5 minutes, the simulation over predicted the concentration in the outermost SC layer, 
but then decreased rapidly to below the experimental data. For 30 minutes incubation, also 
the outer SC layers were over predicted. The 2 h and 6 h data of the outer half of the SC was 
over predicted.  
The prediction of the DSL of the 12.5 mg/ml experiments corresponded moderately with the 
experimental data (fig. 6-5). After 30 minutes, the drug concentration was under predicted, 
after 2 h it was reasonably predicted, and after 6 h it was over predicted.  
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Figure 6-3 Caffeine 1 mg/ml concentration depth profiles in SC. Crosses and the line as a guide to the eye 
represent the simulated depth profiles. The experimental data points are plotted according to 
the individual experiment: A: black circles, B: blue triangles down, C: red diamonds. N=3 for 
each time point.  
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Figure 6-4 Caffeine 12.5 mg/ml concentration depth profiles in SC. Crosses and the line as a guide to the 
eye represent the simulated depth profiles. The experimental data points are plotted 
according to the individual experiment: A: black circles, B: blue triangles down, C: red 
diamonds. N=3 for each time point.  
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Figure 6-5 Caffeine 12.5 mg/ml concentration depth profiles in DSL. Crosses and the line as a guide to 
the eye represent the simulated depth profiles. The experimental data points are plotted 
according to the individual experiment: A: black circles, B: blue triangles down, C: red 
diamonds. N=3 for each time point.  
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6.5 Discussion 
6.5.1 Experimental data 
The FFA concentration depth profiles exhibit a strong decrease in drug concentration from 
the first strips, then reaching a slower decay rate. The shape of the FFA concentration depth 
profiles appears to have a biphasic character, which previously has also been found for other 
drugs, e.g. clobetasol propionate [177] and nortriptyline [178].  
The concentration depth profiles of FFA in the SC are not very different at the various 
incubation times. This is very different to previously presented infinite dose experiments 
[18], where usually for longer incubation times the drug concentration in the skin increases, 
and after reaching the steady-state, a linear decrease of drug concentration over the SC 
depth can be found. For finite dose experiments, it should be expected that SC 
concentration depth profiles first increase and after a certain time, when drug depletion of 
the donor affects the drug delivery to the SC, decrease. This tendency might be detected 
comparing the profiles after 15 min and 4 h. It might be speculated that the experimental 
setup is not sensitive enough to discriminate such differences in SC concentration depth 
profiles for FFA. The FFA concentration depth profiles in the DSL increase over time. Thus, it 
can be assumed that the donor depletion might not yet have an influence on the profiles in 
the DSL.  
The SC concentration depth profiles of caffeine on the other hand seem to be dependent on 
time. At the early time points, the concentration in the first SC layers is higher than for the 
deeper SC layers. After longer incubation, however, the decrease is not so strong any more 
and the profiles appear linear over depth. This is in accordance to what was expected 
according to finite dose kinetics.  
The concentration of caffeine in the SC of the higher concentration (12.5 mg/ml) is roughly 
12.5 times higher than for the lower concentration (1mg/ml). This is in correlation to 
previously published data, where the concentration in the skin increases with increasing 
donor concentration [179]. The caffeine concentrations in the DSL increase over time and no 
impact of the donor depletion can be seen, yet.  
Recently, other non-destructive methods are being investigated at the moment to replace 
the tape-stripping procedure, e.g. Raman spectroscopy [180,181]. However, this method is 
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only suitable for Raman-active substances and the problem of correct determination of the 
depth inside the skin is still under investigation. Also, this method is not able to give 
quantitative results, yet. Therefore, tape-stripping is still the method of choice for 
determination of concentration depth profiles in the SC.  
6.5.2 Correlation between experiment and simulation 
A reasonable agreement between the concentration depth profiles of experiment and 
simulation was found both for FFA and for caffeine. Although simulation of concentration 
depth profiles deviate at some time points from experimental data the agreement between 
in-silico and experiment altogether is reasonable. Especially, if considered that input 
parameters from infinite dose experiments with skin of other donors were employed [18]. 
This is a major advantage as infinite dose experiments are much easier and can be faster 
performed, thus reducing the experimental effort.  
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6.6 Conclusion 
The detailed diffusion model could reasonably predict the concentration depth profiles of 
FFA and caffeine. Thus, this model has the potential to reduce the number of finite dose 
experiments and still give reasonable calculations of the drug concentration in the skin 
layers.  
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7 Summary 
In vivo, the usually employed formulation volume applied to the skin is quite small. Per 
definition, this dose is called a finite dose. As this application scheme is much closer to the in 
vivo situation, finite dose experiments are of special interest also for in vitro experiments.  
In this thesis, finite dose skin absorption experiments were investigated with respect to the 
experimental procedure and setup. Furthermore, mathematical modelling was employed to 
describe or predict the experimental profiles. Most publications dealing with mathematical 
modelling do not compare their results to experimental data. Thus, in this thesis both 
experiment and mathematics are included to elucidate the absorption process to the skin.  
For comparison of experimental data with computational results, correct experimental setup 
and analysis are generally required. To improve the accuracy of the experimental data, the 
tape-stripping procedure was investigated with respect to SC quantification on tape-strips. 
Infrared densitometry proved to be a suitable tool for determining the SC depth reached 
after each strip in vitro, and also to determine the endpoint for complete SC removal. With 
this method, not only the depth resolution was improved, allowing for more precise 
determination of the depth inside the SC, but also the drug concentration in the skin was 
normalized to the actual skin volume removed by each tape-strip. Thus, more accurate 
concentration depth profiles can be obtained for future experiments. Besides, this method is 
easy and not expensive, thus suitable for most laboratories. A widespread use of this 
method would allow for better comparison between results of different working groups. 
Recently, the use of infrared densitometry has been broadened to porcine ear SC [182], 
allowing for the use on animal models. 
The first question resulting from the finite dose experimental setup that was addressed in 
this thesis was the influence of the donor surface distribution on the absorption of the 
substance under investigation. Permeation experiments with the model drugs caffeine and 
flufenamic acid (FFA) with stained aqueous donor solution to delimit the area actually in 
contact with the donor formulation (application area) showed that the application area had 
a great influence on the permeation of the hydrophilic caffeine, but not on the lipophilic FFA. 
Furthermore, in contrast to caffeine, FFA could be found distributed homogeneously over 
the whole incubation area after 41 h. Thus, it can be assumed that the lipophilic FFA 
distributed well over the lipophilic SC and from there was absorbed homogeneously into and 
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through the skin. It can be further presumed that the lipophilicity of the drug may influence 
the effect on the permeation. However, this was actually the first study to investigate the 
influence of the application area on the absorption of solely two compounds to the skin. 
Further studies with more substances are needed to ensure the lipophilicity is indeed 
responsible for this effect and, if possible, determine a limit for lipophilicity until an effect on 
the permeation can be seen.  
Finite dose skin penetration experiments were performed to investigate the mass profiles in 
the different compartments and the concentration depth profiles in the SC and the DSL. The 
experimental setup was thoroughly evaluated and the different skin compartments were 
carefully separated.  
Due to the highly standardized tape-stripping method, the skin was stretched before tape-
stripping to obtain a flat skin surface, thereby increasing the incubated skin area. Thus, the 
incubation area did not correspond to the stripped skin area, requiring a correction of the 
experimental data by a newly-developed stretching factor. This factor could properly correct 
the experimental data for this setup.  
A pharmacokinetic model was developed for the finite dose skin penetration setup in the 
Franz diffusion cell, and a lateral compartment was included, representing the skin parts 
compressed by the device during incubation. The model could describe the mass profiles in 
all compartments for FFA and caffeine reasonably well, also in the lateral compartment. This 
was the first time the mass profiles in the lateral skin part had ever been investigated.  
Furthermore, a 2D diffusion model previously developed for infinite dose was adapted to 
finite dose conditions. The input parameters of this model had previously been derived from 
infinite dose experiments. After adaptation of the model to finite dose, the model could 
predict the finite dose mass profiles relatively well and the concentration depth profiles 
more or less reasonably. Even though the simulated depth profiles not always resulted in the 
same shape as the experiments, the order of magnitude was the same. Thus, the model is 
suitable to predict finite dose profiles.  
As the input parameters remained identical to the infinite dose simulations, it was shown 
that input parameters derived from infinite dose experiments can also be applied to finite 
dose experiments and reasonably predict drug kinetics.  
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8 Zusammenfassung  
In vivo wird üblicherweise ein recht kleines Volumen der Formulierung zur Anwendung auf 
der Haut eingesetzt. Diese Dosis wird per Definition finite dose genannt. Da dieses 
Applikationsvolumen näher an der in vivo Situation ist, sind finite dose 
Hautabsorptionsversuche von besonderem Interesse auch in vitro.  
In dieser Dissertation wurden finite dose Hautabsorptionsversuche durchgeführt und 
untersucht im Hinblick auf den experimentellen Ablauf und den Aufbau. Des Weiteren 
wurden mathematische Modellierungen eingesetzt, um die experimentellen Profile zu 
beschreiben oder vorherzusagen. Die meisten Publikationen, die sich mit mathematischer 
Modellierung beschäftigen, vergleichen die berechneten Daten nicht mit experimentellen 
Daten. Aus diesem Grund wurden in dieser Dissertation sowohl Experimente als auch 
Mathematik eingesetzt, um den Absorptionsprozess in die Haut aufzuklären.  
Ein genauer experimenteller Aufbau und eine exakte Auswertung sind erforderlich, um 
experimentelle Daten mit rechenbetonten Ergebnissen vergleichen zu können. Um die 
Genauigkeit der experimentellen Daten zu erhöhen, wurde die Durchführung des Tape-
strippings im Hinblick auf die Quantifizierung von SC auf Tape-strips untersucht. Hierbei 
zeigte sich Infrarot Densitometrie geeignet, die erreichte SC Tiefe nach jedem Strip in vitro, 
sowie den Endpunkt für die Entfernung des kompletten SC zu bestimmen. Mit dieser 
Methode wurde nicht nur die Tiefenauflösung verbessert, was eine genauere Bestimmung 
der Tiefe im SC erlaubt; zudem wurde die Arzneistoffkonzentration in der Haut normalisiert 
auf das tatsächlich entfernte Hautvolumen je Strip. Folglich können genauere 
Konzentrationsschichttiefenprofile für zukünftige Versuche erhalten werden. Außerdem ist 
diese Methode einfach und preiswert und deshalb geeignet für die meisten Labore. Ein 
weitverbreiteter Gebrauch dieser Methode würde zu einer besseren Vergleichsmöglichkeit 
zwischen den Ergebnissen verschiedener Arbeitsgruppen führen. Vor kurzem wurde gezeigt, 
dass Infrarot Densitometrie auch für die Anwendung am Schweineohr geeignet ist [182], was 
die mögliche Anwendung auf Tiermodelle ausweitet. 
Die erste Frage bezogen auf das experimentelle Setup von finite dose Versuchen, die im 
Rahmen dieser Dissertation untersucht wurden, war der Einfluss der Donorverteilung auf der 
Hautoberfläche auf die Absorption der untersuchten Substanz. Permeationsversuche mit 
den Modell-Arzneistoffen Coffein und Flufenaminsäure (FFA), die in angefärbter wässriger 
  8 Zusammenfassung 
 128
Donorlösung gelöst waren, erlaubten die Bestimmung der tatsächlich mit 
Donorformulierung inkubierten Fläche (Applikationsfläche). Die Versuche zeigten, dass die 
Applikationsfläche einen großen Einfluss auf die Permeation des hydrophilen Coffeins hatte, 
aber nicht auf die der lipophilen FFA. Des Weiteren war FFA im Gegensatz zu Coffein nach 
41 h homogen über die ganze Inkubationsfläche verteilt. Demzufolge kann vermutet 
werden, dass die lipophile FFA sich gut über das lipophile SC verteilt und von dort dann 
homogen in und durch die Haut aufgenommen wird. Es wurde angenommen, dass die 
Lipophilie des Arzneistoffs den Einfluss auf die Permeation bestimmt. Allerdings war dies die 
erste Studie, welche tatsächlich den Einfluss der Applikationsfläche auf die Hautabsorption 
von zwei Substanzen untersucht hat. Weitere Studien mit mehreren Substanzen sind nötig, 
um sicherzugehen, dass die Lipophilie tatsächlich verantwortlich für diesen Effekt ist und, 
wenn möglich, eine Grenze zu bestimmen, bis wann ein Effekt auf die Permeation sichtbar 
ist.  
Finite dose Hautpenetrationsversuche wurden durchgeführt, um die Massenprofile in den 
verschiedenen Kompartimenten und die Konzentrationsschichttiefenprofile im SC und den 
tieferen Hautschichten (DSL) zu untersuchen. Der experimentelle Aufbau wurde sorgfältig 
beurteilt und die verschiedenen Hautkompartimente vorsichtig voneinander getrennt.  
Bedingt durch die hochstandardisierte Tape-stripping Methode wurde die Haut vor dem 
Strippen aufgespannt, um eine glatte Hautoberfläche zu erreichen, wodurch die 
Inkubationsfläche vergrößert wurde. Demzufolge entspricht die Inkubationsfläche nicht der 
gestrippten Hautfläche, was eine Korrektur der experimentellen Daten durch einen neu 
entwickelten Stretching Faktor nötig machte. Dieser Faktor konnte die experimentellen 
Daten für diesen Aufbau nachgewiesenermaßen korrigieren.  
Das pharmakokinetische Modell konnte die Massenprofile von FFA und Coffein in allen 
Kompartimenten angemessen beschreiben, auch im lateralen Kompartiment. Dies war der 
bisher erste Versuch, die Massenprofile im lateralen Hautteil zu untersuchen.  
Außerdem wurde ein zuvor für infinite dose entwickeltes 2D Diffusionsmodell angepasst an 
finite dose Bedingungen. Die Parameter dieses Modells waren zuvor von infinite dose 
Versuchen abgeleitet worden. Nach Anpassung des Modells auf finite dose konnte dieses 
finite dose Massenprofile relativ gut und Konzentrations-Schichttiefenprofile annehmbar 
vorhersagen. Obwohl die simulierten Tiefenprofile nicht immer die gleiche Form wie die 
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Experimente zeigten, war die Größenordnung die gleiche. Deshalb ist das eingesetzte Modell 
geeignet, finite dose Profile vorherzusagen.  
Da die Input Parameter identisch zu den infinite dose Simulationen blieben, wurde gezeigt, 
dass die aus infinite dose Versuchen erhaltenen Input Parameter auch auf finite dose 
Versuche angewendet werden können und Arzneistoffkinetiken richtig vorhersagen können.   
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10.1 Abstract 
Penetration experiments are characterized by segmentation of the skin to separate the 
different skin layers. Generally, skin segmentation is performed in two consecutive 
procedures: First, the major barrier of the skin, the SC, is removed by tape-stripping. 
Afterwards, the deeper skin layers are cut parallel to the skin surface by cryo-sectioning.  
In this chapter, a detailed description of the skin segmentation technique employed in the 
experiments in this thesis is given. This highly standardized segmentation method has been 
described previously by [32].  
Skin segmentation is required in order to investigate the concentration depth profile of a 
drug in the skin. Two parameters are essential for the correct investigation of skin depth 
profiles: first, the amount of skin removed with each sample is required and secondly the 
amount of drug contained in each sample. The determination of the first is described below, 
and the latter is determined by extraction of the drug from the samples.  
From these parameters, the SC depth and the normalized drug concentration (drug amount 
per skin volume of the sample) can be calculated. 
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10.2 Tape-stripping 
Human skin is obtained from abdominal plastic surgery and prepared for storage. For 
performing the experiments, 25 mm diameter pieces of skin are used. After incubation for 
different time intervals with the formulation under study, the SC is removed by successive 
application of adhesive tapes onto the surface of the skin. The corneocytes and intercellular 
lipids adhere to the tape and can be easily removed by this technique.  
For reproducible stripping, the incubated skin specimen is transferred onto a special 
stripping apparatus. To avoid the influence of wrinkles the skin is moderately stretched and 
fixed with small pins on a cork disk. Afterwards, a pre-cut tape is placed on the stripping area 
restricted by a stripping mask made from an inert material. To enhance the contact between 
tape and skin surface the tape is charged with a weight of 2 kg for 10 seconds (fig. 10-1). 
Subsequently, the tape is removed in one swift move. For analytical reasons tapes from 
several strips may be advantageously pooled in corresponding fractions. 
 
 
Figure 10-1 In vitro tape-stripping apparatus. 
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Procedure 
1. The tesa® Film tape (tesa® Film kristall-klar Nr. 57330-00000, Tesa AG, Hamburg, 
Germany) is cut into strips of 16 mm length each with clean scissors  
2. The infrared densitometer (Squame Scan™ 850A, Heiland electronic GmbH, Wetzlar, 
Germany) is put to auto zero with the provided 0% standard filter, and the provided 
grey filter is measured, which should give 33.8% absorption.  
3. An empty tape-strip is placed on the sample holder of the infrared densitometer with 
the adhesive side facing up and the optical density is measured. This value is taken as 
background and will be later subtracted from the values obtained for the samples. 
4. The skin is fixed to the aluminium block filled with cork discs with the help of needles 
(Prym, Stolberg, Germany) and forceps. The skin is properly stretched to eliminate 
wrinkles.  
5. The skin is covered with a Teflon mask with the hole of 15 mm diameter centred on 
the skin to define the stripping area. Then, the setup is fixed by tightening the 
screws.  
6. One tape-strip is placed centrally on the stripping area with the forceps and pressed 
slightly with the back side of the forceps to assure full contact between the tape and 
the skin.  
7. The aluminium block is placed under the stamp of the stripping device and charged 
with a weight of 2 kg for exactly 10 seconds.  
8. The adhesive tape is removed rapidly with forceps in one swift move. 
9. Directly after stripping, each strip is transferred to the sample holder with the 
adhesive side facing up. After three minutes equilibration time, the tape-strip in the 
sample holder is placed under the measuring head. The optical absorption of each 
tape is directly displayed. The tape-strips should always be handled with forceps and 
only the corners of the tape-strip, which will not be measured by infrared 
densitometry, should be touched.  
10. The skin is stripped until the SC is removed completely. This endpoint has to be 
determined previously, for tesa® Film kristall-klar this is the case, when the lower 
limit of quantification (LLOQ) of the IR-D is reached. The LLOQ can be calculated from 
the five fold background noise of an empty tape. Reaching this endpoint no further 
strips are applied. 
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11. The sticky side of the tape-strips are covered with some glass pearls (Merck, 
Darmstadt, Germany) and the tapes are transferred to scintillation vials (20 mL, 
neoLab Migge Laborbedarf-Vertriebs GmbH, Heidelberg, Germany) with the sticky 
side facing up. The glass pearls should prevent the strips from sticking to each other 
and to the vials.  
12. Depending on the nature of the analyzed drug it may be necessary to combine 
several tapes into pools (e.g. “pool 1”: tape n° 1. “pool 2”: tape n° 2. “pool 3”: tapes 
n° 3-5. “pool 4”: tapes n° 6-10. “pool 5”: tapes n° 11-15. “pool 6”: tapes n° 16-20).  
 
10.3 Cryo-sectioning of the deeper skin layers 
After removal of the complete SC by tape-stripping, the stripped skin is frozen by expanding 
carbon dioxide, and slices of 25 µm thickness are cut parallel to the skin surface by means of 
a cryo-microtome (fig. 10-2). The skin segments are transferred into suitable containers for 
drug extraction. For analytical reasons the cuts may be pooled in several fractions.  
 
Procedure 
1. After complete removal of the SC the rest of the skin is frozen, still fixed on the 
aluminium block, in a stream of expanding carbon dioxide until achieving a pale 
appearance. Carbon dioxide is normally used because it is the quickest way to freeze 
skin as it is important to stop drug diffusion. This method is not suitable for volatile 
drugs. 
2. A 13 mm diameter (cryo-section area) biopsy is taken and allowed to thaw. 
3. A drop of water is used to assure the contact between the closed part of the cryo-
bloc and the skin.  
4. The biopsy is mounted (epidermis up) on the drop on the self made aluminium tube. 
This tube with the skin can then be fixed in the cryo-microtome. It has a ring that can 
be moved to different positions. 
5. The spacer ring is placed in the upper position, at the same height as the skin and the 
skin is covered with a glass slide.  
6. The skin is frozen using expanding carbon dioxide again, while retaining the glass 
slide in the same position to obtain a flat surface.  
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7. The glass slide is removed, and the ring put in the lowest position to uncover the 
skin. Then, the tube is fixed with the frozen skin in the cryo-microtome.  
8. All cuts are performed parallel to the skin’s surface (thickness of the skin cuts: 
25 µm). 
9. The cuts are collected in pre-weighed centrifuge tubes and combined in a suitable 
scheme, e.g. incomplete cuts, 4 x 2 cuts, 4 x 4 cuts, 2 x 8 cuts and skin rest.  
10. The centrifuge tubes containing the samples are weighed. The weight of the skin 
samples is later related to the skin thickness. 
 
 
Figure 10-2 Cryo-sectioning of the deeper skin layers. Step 1: The knife moves down and cuts a slice of the 
skin biopsy. Step 2: The skin slice is transferred into a test-tube for extraction and 
quantification. 
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10.4 Extraction of drug from tape-strips and deeper skin layers 
The selection of the extraction medium has to be carefully evaluated for each drug. The 
selected solvent should not remove the glue of the tapes or skin components, as they might 
interfere with the chromatogram or damage the HPLC column. 
To assure the recovery effectiveness in finite dose experiments, a mass balance should be 
carried out. For doing so, the whole absorption experiment is performed as usual and every 
part of the setup in contact with the formulation is extracted with the medium, including the 
rest of the applied formulation. After extraction and analysis of all these samples, a mass 
balance is performed. The recovery should always be between 85 and 115% of the applied 
amount of drug [29] to allow for reliable and comparable results. 
 
10.5 Measurement of the skin thickness 
After segmentation of the skin and extraction of the drug from each segment, the next step 
towards generating concentration-depth profiles is the measurement of both the total 
thickness of the whole skin and also of the thickness of the intact SC.  
 
Complete skin thickness 
The calliper gauge is calibrated to 0 using a glass slide and a cover slip. The skin disc is placed 
on a glass slide and a cover slip is put on the top. The whole skin thickness is measured with 
a tactile probe. The total skin thickness is the mean of five measurements on different 
positions on the skin.  
 
Stratum corneum thickness 
A 4 mm biopsy is punched out of frozen full-thickness skin. A drop of Tissue-Tek® (Sakura 
Finetek, Torrance, CA, USA) is put on a pre-tempered aluminium tube and placed in the cryo-
microtome (Slee, Mainz, Germany) until it starts to freeze. The biopsy is carefully embedded 
in Tissue-Tek® with the SC arranged perpendicular to the metal block surface. Then, the 
whole metal block is placed in the cryo-microtome to allow complete freezing of the biopsy.  
The skin is cut vertically to the surface of the skin in 8 µm thick slices. These slices are 
mounted directly on glass by melting the frozen skin slices to the slides. To achieve this, the 
slides need to be warmer than the slices, e.g. room temperature.  
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Staining of the skin samples, e.g. with haematoxylin, improves the contrast. Afterwards, a 
drop of Fluor Save™ (Calbiochem, San Diego, CA, USA) is applied to the sample and a cover 
slip is placed onto it to protect the sample.  
A conventional light microscope (Leica, Wetzlar, Germany) equipped with a graduate scale 
bar, and a digital camera (Jenoptik, Jena, Germany) are used to visualize the cuts at 400x 
magnification. Image software is used to analyze the pictures (Carl Zeiss Axio Vision Rel. 4.7, 
Carl Zeiss Imaging Solutions GmbH, Göttingen, Germany).  
The mean SC thickness for each skin donor is calculated from microscopic pictures of 
histological cross-sections on at least 10 different positions (fig. 10-3). 
Skin should not be used after 6 months storage at -26°C as not only the permeability 
characteristics might be changed, but also the SC thickness [39,41].  
 
 
Figure 10-3 Histological cross-section of human skin at 400x magnification. 
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10.6 Data treatment and plotting 
Normalized drug concentration can be plotted versus skin depth to see the drug distribution 
within the different skin layers after the selected incubation times. The concentration depth 
profiles provide information about:  
 the influence of the incubation time, drug concentration, and the vehicle on drug 
distribution  
 saturation of the SC  
 formation of depots in the different skin layers 
Please note that the first tape-strip also removes rests of formulation that can be left on the 
skin surface after cleaning. Therefore, the first strip is usually not plotted in drug 
concentration skin depth profiles [135]. However, it has to be taken into account for 
determining the SC depth as well as for mass balance.   
 
A step-by-step calculation of the depth in the SC and in the DSL is presented below:  
 
• Corrected absorption value for a single tape-strip 
  * 0i ix x x= −        (Equation 10-1) 
xi:  absorption of a tape-strip measured by IR-D and corrected for absorption of 
empty tape 
    :  absorption measured by IR-D, non-corrected value 
x0:  absorption of an empty tape measured by IR-D 
i:  tape-strip number 
 
*
ix
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• Absorption value for pooled strips 
  ( )
j
pool n i
i h
x x
=
=∑        (Equation 10-2) 
xpool(n):   sum of absorption of strips in pool n containing strips h-j measured by IR-D 
xi:  absorption of i-th tape-strip measured by IR-D and corrected for empty tape 
i:   tape-strip number 
h:  first strip belonging to the n-th pool 
j:  last strip belonging to the n-th pool 
 
• Relative SC thickness removed per pool 
 
max
( ) max max
*
1
/
rel n
nj
i n n i
i h i
d x X with X x
= =
= =∑ ∑    (Equation 10-3) 
d*rel(n):  relative  SC thickness removed per pool n 
xi:  absorption of i-th tape-strip measured by IR-D and corrected for empty tape 
h:  first strip belonging to the n-th pool 
j:  last strip belonging to the n-th pool 
nmax:  total number of tape-strips 
       :    absorption of total number of tapes nmax   
 
• Absolute SC thickness of the n-th pool 
  * * ( )n tot rel nd d d= ⋅        (Equation 10-4)
  
     :  absolute SC thickness of  the n-th pool 
dtot:  total SC thickness 
d*rel(n):  relative  SC thickness removed per pool n 
 
• SC depth after nn pools of tape-strips 
  *
1
n
n
n
n n
n
d d
=
=∑        (Equation 10-5) 
       :  SC depth after nn pools of tape-strips 
     :  thickness of  the n-th pool 
*
nd
maxn
X
nn
d
*
nd
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• Absolute thickness of pool l of cuts 
  
max
max max
*
N
1 1
/    W
Nl
l tot k N k
k k
L L w W with w
= =
= ⋅ =∑ ∑   (Equation 10-6) 
L
*
l:  absolute thickness of pool l of cuts  
Ltot:  total thickness of the stripped skin 
wk:  weight of the pool of cuts / rest of the skin 
k:  lower number of pools of cuts 
l:  upper number of pools of cuts 
Nmax:  total number of pools 
        :  weight of total number of pools 
 
• Depth of deeper skin layers after pool l of cuts 
  ∑
=
=
l
k
*
kl LL
1
        (Equation 10-7) 
Ll:  depth into the deeper skin layers after pool l of cuts 
L
*
k:  thickness of pool k of cuts  
 
• Drug amount in pool n 
  *
n nEX EX EX
m c V=        (Equation 10-8) 
         :  extracted drug amount of pool n 
       :  drug concentration in the extract of n-th pool of tape-strips 
VEx:  volume of the extracting agent (e.g. 2.0 ml) 
 
maxN
W
nEx
c
nEX
m
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• Normalized drug concentration in SC for n-th pool of tape-strips 
  
*
nEx Ex
n
T n
c V
c
A d
⋅
=
⋅
        (Equation 10-9) 
cn:  normalized drug concentration in skin for n-th pool of tape-strips 
      :  drug concentration in the extract of n-th pool of tape-strips 
VEx:  volume of the extracting agent (e.g. 2.0 ml) 
AT:  area of tape-stripping (e.g. 1.767 cm
2
) 
      :  thickness of SC removed by tape-strips of pool n  
 
• Normalized drug concentration in deeper skin layers for l-th pool of cuts 
  
*
lEx Ex
l
C l
c V
c
A L
⋅
=
⋅
        (Equation 10-10) 
cl:  normalized drug concentration in skin for l-th pool of cuts 
       :  drug concentration in the extract of l-th pool of cuts 
VEx:  volume of the extracting agent (2.0 ml) 
AC:  area of cryo cutting (1.327 cm
2
) 
     :  thickness of viable skin removed by cuts of pool l 
 
• Calculation of the middle of segment 
 
( )
2
h j
x
d d
d
+
=    (Equation 10-11) 
dx:  middle of segment 
dh:   depth before first strip of the pool 
dj:  depth after last strip of the pool 
 
• Cumulative drug amount in SC 
  ∑
=
=
max
n
n
i
EXmQ
2
        (Equation 10-12) 
Q:  cumulative drug amount in SC without strip 1 
mEXn:  extracted drug amount of pool n  
nmax:   total number of tapes 
 
*
nd
*
lL
nEx
c
lEx
c
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With these calculations, concentration depth profiles can be established, for an example see 
fig. 10-4. On the following pages, this example for the calculation of concentration skin 
depth profiles is given.  
   
For the calculations the following values are used: 
 Stripping area (AT):     1.76 cm² 
 Area of cryo-cuts (AC):    1.327 cm² 
 Extraction volume for samples (mEx):  2 ml 
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Figure 10-4 Concentration depth profiles obtained from the example calculation in tables 10-1 to 10-3. 
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Table 10-1 Determination of the depth within the SC 
i xi* xi pool ( )
j
pool n i
i h
x x
=
=∑  
 * * ( )n tot rel nd d d= ⋅
 
 
measure
d by IR-D 
corrected  
(from IR-
D) 
 
sum of IR-D 
absorption of 
strips  in pool n 
relative 
amount of 
SC removed 
per pool 
thickness of 
segment 
 [%] [%] 
 
[%] [%] [µm] 
empty 
strip 6.7  
 
   
1 21.2 14.5 #1; (h=j=1) 14.5 7.2 1.08 
2 18.8 12.1 #2; (h=j=2) 12.1 6.0 0.90 
3 16.9 10.2 
#3; (h=3; 
j=5) 34.7 17.3 2.59 
4 19 12.3     
5 18.9 12.2     
6 22.3 15.6 
#4; (h=6; 
j=10) 78.3 39.0 5.85 
7 24.1 17.4     
8 20.1 13.4     
9 21.7 15     
10 23.6 16.9     
11 18.4 11.7 
#5; (h=11; 
j=16) 43.5 21.7 3.25 
12 17.8 11.1     
13 15.3 8.6     
14 12.3 5.6     
( ) max
* /
rel n
j
i n
i h
d x X
=
=∑
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15 13.2 6.5     
16 11.8 5.1 
#6; (h=15; 
j=20) 17.5 8.7 1.31 
17 11.4 4.7     
18 10.4 3.7     
19 9.3 2.6     
20 8.1 1.4     
max
1
n
i
i
x
=
∑  334.6 200.6     
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Table 10-2 Determination of the depth into the viable skin layers  
pool 
wk 
 
 
 
weight of viable skin 
removed by pool 
thickness of segment 
 [mg] [µm] 
#7 3.06 60.36 
#8 3.07 60.55 
#9 7.46 147.14 
#10 9.29 183.24 
#11 27.16 535.71 
#12 (rest of skin) 178.53 3521.38 
∑
=
=
12
7
#
#
i
i
iw  228.57 
cumulative weight of 
viable skin removed by all pools 
max
*
1
/
l
l tot k N
k
L L w W
=
= ⋅∑
 Table 10-3 Calculation of concentration-depth profiles in the SC and the viable skin layers 
pool cEx *
n nEx EX EX
m c V=  
max
* /
j
n tot i n
i h
d d x X
=
= ⋅∑  dn ( )1 2n nd d −+  
max
/
j
n T tot i n
i h
V A d x X
=
= ⋅ ⋅∑  *n
Ex Ex
n
T n
c V
c
A d
⋅
=
⋅
 
 experimental extracted amount thickness of segment depth into the SC middle of segment volume of segment concentration 
 [µg/ml] [µg] [µm] [µm] [µm] [cm
3
] [µg/cm
3 
] 
#1 0.5334 1.0668 1.08 1.08 0.54 1.916E-04 5568.24 
#2 0.2268 0.4536 0.90 1.99 1.54 1.599E-04 2837.21 
#3 0.2742 0.5484 2.59 4.58 3.29 4.585E-04 1196.11 
#4 0.1377 0.2754 5.85 10.44 7.51 1.035E-03 266.20 
#5 0.0645 0.1290 3.25 13.69 12.07 5.748E-04 224.44 
#6 0.0220 0.0440 1.31 15 14 2.312E-04 190.29 
 ∑
=
=
max
n
n
i
EXmQ
2
 TAQ     
 
 
 
amount in SC  
(without first strip) 
normalized for  
stripping area 
   
 
 
 [µg] [µg/cm
2
]      
 1.4504 0.8208      
 Table 10-3 second part 
pool cEx *
n nEX EX EX
m c V=  
max
* /l tot k NL l w W= ⋅  dtot+li ( ) 21−++ iitot lld  
max
/k C tot k NV A L w W= ⋅ ⋅  *
lEx Ex
l
C l
c V
c
A L
⋅
=
⋅
 
 experimental extracted amount thickness of segment depth inside the skin middle of segment volume of segment concentration 
 [µg/ml] [µg] [µm] [µm] [µm] [cm
3
] [µg/cm
3 
] 
#7 0.1352 0.2704 60.36 75 45 8.009E-03 33.76 
#8 0.0678 0.1356 60.55 136 106 8.035E-03 16.88 
#9 0.0654 0.1308 147.14 283 209 1.953E-02 6.70 
#10 0.0589 0.1178 183.24 466 375 2.432E-02 4.84 
#11 0.0532 0.1064 535.71 1002 734 7.109E-02 1.50 
#12 0.0504 0.1008 3521.38 4523 2763 4.673E-01 0.22 
 
∑
=
12#
7#i
EX l
m  C
i
EX Am l /
12#
7#
∑
=
 
     
 
amount in viable skin  
normalized for  
cutting area  
    
 [µg] [µg/cm
2
]      
 0.8618 0.6494      
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11 Abbreviations 
AC:  area of cryo-sectioning (1.327 cm²) 
AT:  area of tape-stripping (e.g. 1.767 cm
2
) 
BCA:  bicinchoninic acid 
BSA:   bovine serum albumin 
nExc :  drug concentration in the extract of n-th pool of tape-strips 
cl:  drug concentration in skin for l-th pool of cuts 
cn:  drug concentration in skin for n-th pool of tape-strips 
D:  diffusion coefficient 
d*rel(n)  relative SC thickness removed per pool n 
d*n:  absolute SC thickness of the n-th pool 
Da:  Dalton 
dnn:  SC depth after nn pools of tape-strips 
DSL:  deeper skin layers 
dtot:  total SC thickness 
dx:  middle of segment 
FFA:  flufenamic acid 
i:   tape-strip number 
IR-D:  infrared densitometry 
hs:  first strip belonging to the n-th pool 
J:  flux through a membrane 
Jss:  steady-state flux 
js:  last strip belonging to the n-th pool 
Ko/w:  octanol/water partition coefficient 
kp:  permeability coefficient 
l:  thickness of the membrane 
L
*
k:  depth in the deeper skin layers after pool k of cuts 
L*l:  absolute thickness of pool l of cuts 
Ll:  depth into the deeper skin layers after pool l of cuts 
LLOQ:  lower limit of quantification 
Ltot:  total thickness of the stripped skin 
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mEXn:  extracted amount of drug of pool n 
MW:  molecular weight 
nmax:   total number of tape-strips 
Nmax:  total number of pools of cuts 
Q:  cumulative drug amount in SC without strip 1 
Qt:  Cumulative permeated drug amount over time 
SC:  stratum corneum 
t:  time 
tlag:  lag time 
TEWL:  transepidermal water loss 
VEx:  volume of the extracting agent (e.g. 2.0 ml) 
wk:  weight of the pool of cuts / rest of the skin 
WNmax:  weight of total number of pools of cuts 
xi:  absorption of a tape-strip measured by IR-D and corrected for absorption of 
empty tape 
xi*:  absorption measured by IR-D, non-corrected value 
Xnmax:   absorption of total number of tapes nmax 
xo:  absorption of an empty tape measured by IR-D  
xpool(n):  sum of absorption of strips measured by IR-D in pool n containing strips h-j 
measured by IR-D 
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